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Abstract 
 
The mixed-lineage leukaemia 1 protein is a histone methyl-transferase that deposits the 
gene activating H3K4 trimethyl mark,  and is often mutated in leukaemia. MLL1 is normally 
associated with a cohort of cofactors, but the mechanisms regulating the histone methyl-
transferase activity remain unclear. Here I examine the role of Msk1, a downstream kinase 
of the MAP-kinase pathway, in regulating MLL1 activity. Msk1 is known to deposit the H3S10 
phosphorylation mark, which was found to stimulate MLL1’s methylation activity in vitro. 
Here I demonstrate that MLL1 and Msk1 can be immunoprecipitated and their patterns of 
genomic binding show an overlap at ~30 of sites, suggesting a direct functional interaction. 
In transient MLL1 and Msk1 knock-down cells, known MLL1 target genes were down-
regulated and at a global level, 30% of all responding genes were regulated in the same 
manner. Furthermore, key histone modifications at MLL1 target genes change in Msk1 
knock-down cells, suggesting that  histone cross-talk within the MLL1 complex acts as a 
means of gene regulation.  Finally, cell cycle studies suggest MLL1-Msk1 cross-talk may 
stimulate MLL1-driven gene expression after mitosis. These findings suggest that MLL1 is 
regulated by Msk1 and therefore by extracellular signals via the MAP-kinase pathway. 
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1 Introduction 
Development starts with fertilization, resulting in a stem cell with a unique and individual set 
of genes. This stem cell gives rise to every cell in the final organism, which all carry the same 
genetic information, but vary significantly in their phenotype defined by characteristic 
patterns of gene expression and silencing (Figure 1.1). These patterns are established by 
epigenetic mechanisms that do not alter the DNA sequence and need to be maintained 
through DNA replication, chromatin assembly and DNA condensation in mitosis. Bird defines 
epigenetic events as “the structural adaptation of chromosomal regions so as to register, 
signal or perpetuate altered activity states” (Bird 2007).  Although epigenetic events can be 
short lived, under certain circumstances they need  to be stable to be passed onto daughter 
cells, which led to the hypothesis of the “epigenetic memory” of the cell (Riggs & Porter 
1996). The foundation of all epigenetic mechanisms are proteins that can establish, read, 
modify and erase epigenetic modifications and regulate the access of the transcription 
machinery to the DNA (Inbar-Feigenberg et al., 2013). Several mechanisms are known, 
including DNA methylation (Berger et al. 2009), post-translational histone modification 
(Turner 2005), histone variants (Khorasanizadeh 2004), nucleosome positioning (Schones et 
al. 2008) and ncRNA (ENCODE project Consortium 2012), which work together to establish 
the ‘epigenetic state’ of individual genes and generally the whole cell (Jirtle & Skinner 2007). 
However, epigenetic mechanisms do not only define constitutive gene expression, but also 
contribute to the response to extracellular signalling (Jaenisch & Bird 2003). The epigenome 
therefore has an important regulatory  function and directly links the environment to gene 
activity (Franklin & Mansuy 2010). 
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 Figure 1.1: Development and Epigenetic mechanisms. All the cells in an individual carry the same 
underlying genetic information, which was created at conception.  Despite the common DNA-sequence, 
differentiated cells vary in their phenotype due to different patterns of gene expression. Epigenetic 
mechanisms play an important role in establishing these patterns during development. 
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1.1 Chromatin Organization 
In prokaryotes, genes are in an unrestricted ground state and gene expression is only 
dependent on RNA Polymerase II binding to the promoter. The eukaryotic genome however 
is much more complex than the prokaryotic, with long stretches of non-protein-coding 
sequences. Hence gene expression not only depends on RNA Polymerase II access, but also 
on transcription factor binding and regulatory sequences, which can be several megabases 
away from the promoter (Struhl et al. 1999). In order to initiate transcription ‘transcription 
factories’, a large battery of proteins (e. g. transcription factors), associate at active genes 
and participate in transcription and co-transcriptional RNA processing (Buckley & Lis 2014). A 
key event is the recruitment of RNA Polymerase II and the general transcription factors at 
the core promoter, forming the Pre-Initiation-Complex, in which the polymerase is in a 
poised state. Only after its phosphorylation at the C-terminal domain (Phatnani & Greenleaf 
2006) does Polymerase II leave the complex and  move on to the elongating state (Müller & 
Tora 2014). The complexity of the eukaryotic genome and the gene expression require a high 
level of organization of the DNA in the nucleus.  
Therefore in eukaryotes  the primary role of the nucleus is the storage, retrieval and 
replication of genetic information, which requires the organization and compaction of ~2 m 
of DNA in mammals (Woodcock & Ghosh 2010). In Figure 1.2 the different levels of 
chromatin organisation are shown. The 2nm DNA fibre is wrapped twice around the 
nucleosome, forming an open zigzag string or 11nm fibre, often referred as the “beads on a 
string” structure (Olins & Olins 1974). Adjacent nucleosomes are linked with DNA, which 
varies in length in a cell- and species-specific manner. Nucleosomes subsequently self-
assemble  into the “30nm fibre”, a regular array in which nucleosomes are packed on top of 
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one other (Robinson & Rhodes 2006). The 30nm is the first level of transcriptionally inactive 
chromatin. It has been assumed that chromosomes in interphase consist of either the 11nm 
(active) or 30nm (inactive) chromatin fibre (Gall 1966, Dorigo et al. 2004). Chromatin can be 
further compacted, aided by chaperone proteins, which prevent inappropriate interaction. 
The mechanisms however are unknown (Hansen et al. 2010). In vitro studies on 
chromosomes propose that condensin acts as a scaffolding and interlinking protein, which 
supports higher order structures (Maeshima & Eltsov 2008). During mitosis chromosomes 
are visible. They  are the most condensed form of DNA and about 10,000 times shorter than 
the non-condensed DNA fibres (Felsenfeld & Groudine 2003).  
However, recent reports claim, that this model of hierarchical DNA packaging (which is 
mostly based on in vitro studies) needs to be revised. It is now known that chromosomes are 
divided into hundreds of domains with different protein compositions (Bickmore & van 
Steensel 2013). New technologies (like Chromatin Conformation Capture techniques) have 
found that in vivo chromatin is packed into 11-nm fibres, which form 3-dimensional 
chromatin domains independent of higher order structures (Razin & Gavrilov 2014). It has 
been shown, that interphase chromosomes occupy distinct chromosome territories. These 
‘topological domains’ have well defined boundaries, which are engaged with proteins such 
as the insulator protein CTCF (Bell et al. 1999) and are conserved across different species 
(Dixon et al. 2012). 
In chromatin formation the nucleosome plays a central role, as the basic unit of chromatin 
condensation. It is basically the same in all eukaryotes and is one of the most highly 
conserved structures (Luger et al. 1997). The nucleosome consists of a stretch of DNA, which 
is wound around eight histone proteins. Two copies of each histone protein (H2A, H2B, H3 
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and H4), as shown in Figure 3.2 B, assemble together and form a histone octamer. Around 
this 145-147 base-pairs of DNA are wrapped in a left handed super-helix (Luger et al. 1997). 
The shape and the charge on the nucleosome surface facilitate most of the histone-histone 
and histone-DNA interactions. This makes the nucleosome an essential component for 
higher chromatin structure (Garcia-Ramirez et al. 1992; Chodaparambil et al. 2007). From 
this nucleosome core the N-terminal domains of the histones (“tails”) protrude (Figure 3.3 
A). They are flexible and highly mobile with a large number of charged residues (Banères et 
al. 1997). In low salt conditions they dissociate from their original binding positions on the 
nucleosome and therefore cannot be crystallized. However, in vivo studies have shown that 
they can make contact with other histones (du Preez & Patterton 2013). The N-terminal tails 
can interact within the same nucleosome but also with neighbouring nucleosomes. It is now 
thought that the tails support the formation of the higher order structures and may even be 
involved in  the binding to the DNA or chromatin proteins (Zheng & Hayes 2003). For 
example tails of histone H4 bind to defined regions (‘acidic patches’)  of neighbouring 
nucleosomes and help to compact the higher order structure of chromatin (Kalashnikova et 
al. 2013).  In higher eukaryotes the nucleosome is stabilized by the linker histone H1, which 
sits on top of the core-nucleosome. H1 is positively charged and stabilizes the binding of the 
negatively charged DNA to the nucleosome (Harshman et al. 2013). Furthermore, recent 
findings suggest that histone H1 binding, in concert with the length of linker DNA between 
two nucleosomes, may have an influence on the shape and formation of the 30 nm fibre 
(Routh et al. 2008). 
Although chromatin needs to be highly organized, it also needs to be kept flexible and 
accessible in order to be able to respond to environmental and developmental stimuli (Lange 
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et al. 2011). In general there are two different types of chromatin. In 1928, Heitz observed, 
that some chromatin regions stayed condensed during the cell cycle (Heitz 1928). He called 
those regions heterochromatin (Zacharias 1995). Today it is known, that heterochromatin is 
highly condensed and gene-poor. This is generally distinguished into constitutive 
heterochromatin, in which genes are poorly expressed and found at distinct genomic 
locations (eg. centromeres or telomeres, Tamaru 2010). In addition facultative 
heterochromatin exists, in genomic regions that can adopt an open or compact 
conformation and that are often associated with differentiation. The most prominent 
example for facultative heterochromatin formation is the inactivation of the second X-
chromosomes in female cells (Trojer & Reinberg 2007). Euchromatin on the other hand is 
less condensed and transcriptionally active. It is thought that insulator elements in the DNA 
sequence prevent the interference of hetero- and euchromatin and which also block 
enhancer activity at inappropriate promoters. They are bound by proteins, like CTCF a highly 
conserved zinc-finger DNA binding protein (Bell et al. 1999; Ghirlando et al. 2012). 
It is not yet understood how hetero- and euchromatin domains are formed. Yet nucleosome 
arrays are highly dynamic even in a very condensed state. In a study, which used FRET 
microscopy on fluorescence-labelled nucleosome arrays, it was shown that chromatin 
undergoes conformational fluctuations, exposing sites on the nucleosome (Poirier et al. 
2010). These spontaneous chromatin fibre dynamics allow for the invasion and action of 
DNA processing protein complexes and may allow chromatin conformation changes (Poirier 
et al. 2010). Nevertheless, it is now accepted that the chromatin state influences gene 
transcription (Dillon 2004) and that compaction of chromatin leads to inhibition of 
transcription initiation and elongation by RNA polymerase II (Hansen & Wolffe, 1992) 
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Figure 1.2: Chromatin Organization. (A) The DNA double-helix is first wrapped twice around the 
nucleosome core, the fundamental packaging unit of chromatin, leading to an open “bead on a string” 
structure.  This fibre is then further condensed into the 30-nm fibre and subsequently forms unknown 
higher order structures. Finally the chromosome in mitosis is the most condensed form of chromatin 
(Maeshima & Eltsov 2008).  (B) X-ray crystal structure of the nucleosome core, which consists of histone 
proteins (H2A, H2B, H3 and H4 (Weber & Henikoff 2014, adapted from Luger et al. 1997). 
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1.2 Histone Modifications 
Nucleosomes are an important structural component of chromatin.  However, the histone 
tails, which project from the nucleosome core, are targeted by specialized enzymes that 
deposit modifications on specific amino acid residues after translation (Bhaumik et al. 2007). 
Most common are acetylation of lysines, methylation of lysines and arginines, and 
phosphorylation of serines, threonines or tyrosines. These modifications are small chemical 
groups and are deposited at distinct residues of the histone tails by specialized histone 
modifying enzymes, for example methyltransferases deposit and demethylases remove 
methyl-groups (Figure 1.3 A & B). These enzymes normally work in pairs, in which one class 
of enzymes oppose each others effect. The level of histone modification depends on a 
dynamic equilibrium of the enzymes (Turner 2012). While residues can only be mono-
acetylated or mono-phosphorylated, methylation shows a greater extent of variation.  Lysine 
methylation can differ between mono-, di- or tri-methylation, whereas di-methylated 
arginines can be symmetric or asymmetric (Kouzarides 2007).  However the landscape of 
post-translational modifications is more complex with many more modifications known and 
modifications found on the fold of the N-terminal domains or even within  the globular 
domain (Rothbart & Strahl 2014). By now over 100 modifications are known with a great 
variety of formats  (Xu et al. 2014). For example, peptides can be added to the histone tails, 
like ubiquitin (West & Bonner 1980) or SUMO (Shiio & Eisenman 2003), and complex 
chemical groups like ADP-ribose (Martinez-Zamudio & Ha 2012) or biotin (Camporeale et al. 
2004). However, post-translational modifications can also affect the histone tail itself, like 
deimination (conversion of arginine residues into citrulline, Cuthbert et al. 2004) or histone 
tail clipping (histone H3 is shortened by cleavage after alanine 21, Santos-rosa et al. 2012). 
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It is generally accepted, that histone modifications play an important role in gene regulation, 
though the precise mechanism for all modifications is still elusive (Henikoff & Shilatifard 
2011). Nevertheless, key histone modifications have been studied intensively and are 
associated with specific functions. Histone H3 lysine 9 acetylation (H3K9ac) and histone H3 
lysine 4 tri-methylation (H3K4me3) are generally associated with active genes, whereas 
histone H3  lysine 27 tri-methylation (H3K27me3) is generally associated with silent genes 
(Barski et al. 2007) . ChIP-Seq experiments generated high-resolution maps of these histone 
modifications across the genome, revealing their position across active or silent genes 
(Figure 1.3 C). These experiments showed a spike of H3K4me3 and H3K9ac over the 
promoter region (TSS) of active genes and a lower background level of H3K27me3. In 
contrast, on silent genes H3K27me3 rises slightly, whereas H3K4me3 and H3K9ac abundance 
stays at a background level (Yin et al. 2011).   
In general,  cell type specific gene expression is controlled by the availability of transcription 
factors and their accessibility  to chromatin, which is controlled by epigenetic mechanisms, 
like histone modifications (Schones & Zhao 2008).  So far three theories have been proposed 
to explain their functions.  
(I) Histone tails contain a high percentage of positively charged arginine and lysine residues, 
which facilitates interaction with the negatively charged DNA.  It has been shown that 
acetylation alters the charge of histone tails by neutralizing the positive charge of lysine 
residues. Hyper-acetylation of the histone tails leads to an accumulated effect of charge 
neutralisation of the tails and therefore to an opening of chromatin structure allowing gene 
transcription (Dion et al. 2005). For example, artificially induced hyper-acetylation at H4K16 
inhibited the formation of nucleosome arrays into more compact fibres (Shogren-Knaak et 
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al. 2006).  A similar role has been proposed for phosphorylation, which brings a negative 
charge to the histone tail and therefore may create repulsion between the negatively 
charged DNA and the histone (Mahadevan et al. 1991; Banerjee & Chakravarti 2011).  
(II) Certain histone modifications are associated with specific transcriptional states. 
Acetylation in general is associated with actively transcribed genes, as well as H3K4me3. 
H3K27me3 on the other hand is associated with repressed genes (Lee & Mahadevan 2009).  
In the “histone code” model it is suggested that chromatin binding proteins can be recruited 
by histone modifications as they contain specialized domains, which recognize defined 
histone modifications. Thus different histone modifications can function together to signal 
distinct chromatin states (Strahl & Allis 2000).  
(III) More recently it has been proposed, that histones work as signalling integration 
platforms. There are a variety of histone modifications and most do not seem to have a 
direct functional output. This leads to the suggestion that histone modifications summate 
the response to multiple external signals, which results in only a small directed output. 
Although signals on their own can either activate or inactivate gene expression they are 
interpreted in the context of the histone landscape. Thus,  although every incoming signal 
changes the histone modification landscape, it is proposed that only the entirety of the 
modifications is interpreted,  via recruiting proteins to the DNA  (Badeaux & Shi 2013). 
Histone modifications can be stable and unchanging throughout a cell’s life, or highly 
dynamic and  rapidly changing,  appearing  or disappearing on a nucleosome within minutes 
after an external stimulus  (Kouzarides 2007). For example the inactivation of one X-
chromosome in female mammalian cells is associated with the stable establishment of 
facultative heterochromatin. This is hypoacetylated and hallmarked with H3K27me3, 
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H3K9me2, H4K20me1 and H2AK119ub1, whereas constitutive heterochromatin is 
hypoacetylated and marked with H3K27me1, H3K9me3 and H4K20me3. Nonetheless the 
composition of histone modification on the X chromosome can vary in different regions and 
probably the combination of different modifications signal the chromatin state (Brinkman et 
al. 2006). In contrast, a study on histone modifications in yeast during replication has shown 
that replication is accompanied by dynamically changing modifications, especially histone H3 
and H4 acetylation, such as H3K56ac, which increases from low levels in G1 to high levels in 
S-phase and then drops back (Unnikrishnan et al. 2010).  
Additionally different modifications have different turnovers. Histone methylation usually 
has a slower turnover than acetylation or phosphorylation, which only have a half-life of 1-5 
minutes. Furthermore, silencing marks are more stable than activating histone marks 
(Clayton et al. 2006; Zee et al. 2010). This indicates that long-term changes, as well as 
immediate, short term changes to the chromatin landscape can be mediated by histone 
modifications (Lee & Mahadevan 2009).  
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Figure 1.3: The Nucleosome.  (A) Nucleosomes are histone octamers with ~146 bp DNA wrapped around it. 
Histones have two domains: the globular domain and the N-terminal ‘tail’ domain. The globular domain 
forms the core of the nucleosome, around which the DNA is wrapped, while the tail domains protrude from 
it. (B) Modifications are highly specific for distinct residues on the tails (Ph=phosphorylation, 
Me=methylation, Ac=acetylation, figure by Charlotte Rutledge). (C) ChIP-Seq experiments generate high 
resolution maps of key histone modification distribution across genes. These indicated the average pattern 
of modifications across the transcriptional start site (TSS) (adapted from Barski et al. 2007 and Yin et al. 
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1.3 Histone Crosstalk 
The vast number of histone modifications in a small area implicates that they influence each 
other, providing regulatory cross-talk.  For example histone H3 phosphorylation at serine 10 
(H3S10p) is involved in two opposite chromatin states.  Mitotic chromosomes are highly 
phosphorylated and have very compacted chromatin (Hsu et al. 2000). On the other hand 
active genes are also marked with H3S10p, implicating that it’s readout is influenced by 
other modifications (Mahadevan et al. 1991; Nightingale et al. 2007).  
Cross-talk can take place in various forms (Figure 1.4). It can be limited to one histone tail 
(cis) or can occur between modifications on different histone tails (trans). The outcome of 
the affected modification can be enhanced (positive cross-talk) or can be blocked (negative 
cross-talk) (Nightingale et al. 2006). Finally it can be direct, affecting the histone 
modifications on the tails, or it can be indirect, affecting histone binding proteins (Latham & 
Dent 2007; Fischle 2008).  
The most obvious form of direct cross-talk is shown in Figure 1.4 A. Some residues can be 
modified in different ways. H3K4 can be either acetylated or methylated, so blocking each 
other. Another example of negative direct cross-talk is in ES cells  where key developmental 
genes are kept in a bivalent state by marking them  with the activating H3K4me3 mark, as 
well  as with the repressive H3K27me3 mark, neutralizing the outcome of the individual 
modifications (Bernstein et al. 2006).  
However cross-talk can also involve the enzymes, which deposit modifications. Dot1 is a 
methyltransferase that targets H3K79, yet for efficient methylation, H2BK123 needs to be 
ubiquitinilated (Figure 1.4 B). In contrast, for the ubiquitination of H2B, methylation of 
H3K79 is not required (Ng et al. 2002). 
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In Figure 1.4 C, an example of indirect cross-talk is given. The HP1 protein is an essential 
regulator of epigenetic gene expression and important for chromatin stability during mitosis. 
It can bind to methylated lysine 26 on histone H1.4, though when the same histone is 
phosphorylated at serine 27, HP1 cannot bind anymore (Daujat et al. 2005).  
Another level of complexity in cross-talk was described for the regulation of the FOSL1 gene 
(Figure 1.4 D). After stimulation the FOSL1 enhancer is phosphorylated at H3S10. The  14-3-3 
protein can bind then to the phosphorylated mark and activate the acetyltransferase MOF, 
which deposits H4K16 acetylation. At this point BRD4 can bind to the two marks and trigger 
the release of the paused polymerase II at the FOSL1 promoter (Zippo et al. 2009).  
 Crosstalk of different types of histone modifications acting in a combinatorial manner, 
allows fine-tuning of nuclear events and the integration of different cellular signalling 
pathways at the chromatin level (Zhang & Pradhan 2014). It also enables the histones to 
carry a vast amount of information. For example the first 10 amino acids of histone H3.1 
(ARTKQTARKS) can be targeted by 19 different modifications, some of them exclusive. This 
results in 60 different modified peptides, expanding the number of possible single modified 
histone tails (Schwammle et al. 2014).   More complexity is added by the fact that histone 
modifications also cross-talk to other epigenetic pathways, like DNA methylation and 
ncRNAs (Suganuma & Workman 2011). 
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Figure 1.4: Histone cross-talk. Histone modifications can influence each others functional output. Here are 
some examples given with more details in the text. (A) Negative cross-talk means that one modification 
blocks another one. Here H3K4ac prevents H3K4me3 in cis (on the same histone) (B) Positive cross-talk 
means one modification enhances another modification. Here H2B ubiquitination stimulates Dot1 
methyltransferase activity in trans (on another histone). (C) Cross- talk can be indirect not affecting any 
histone modifications. For example HP1 cannot bind to its normal target H1.4K26 methyl-mark, when 
blocked by the H1.4S27 phospho-mark. (D) Cross-talk can be very complex. Here the 14-3-3 protein binds to 
H3S10p, which then activates MOF, which deposits the H4K16 acetyl-mark. This allows the binding of BRD4 
to H3S10p and H4K16ac.  
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1.4 Readout of histone modifications 
 The histone modification landscape is a flexible, constantly changing environment. This 
requires specialized proteins, which can either deposit histone modifications (‘writer’), 
remove them (‘eraser’) or recognize them (‘reader’) (Strahl & Allis 2000).  The level of 
histone modifications at a locus is therefore determined by the balanced activity of the 
writer and the eraser proteins (Figure 1.3 A). For example, acetylation is deposited by acetyl-
transferases and removed  by deacetylases (Wang et al. 2009). Phosphorylation is set  by 
kinases in response to upstream signalling pathways and opposed by phosphatases (Shimada 
et al. 2010). Lysine methylation is catalysed by methyl-transferases, which nearly all contain 
catalytic SET domains and removed by demethylases  (Black & Whetstine 2013).  Histone 
modifications provide highly selective binding sites for reader proteins, a class of proteins 
that contain different highly conserved domains, which recognize histone modifications at 
certain residues (Mellor 2006).  In Figure 1.5 a selection of them are shown.  
The bromo-domain for example bind specifically to acetylated lysines (Sanchez et al. 
2014). This domain was first discovered on the brm-gene in Drosophila and it was recognized 
that this 77 amino-acid motif is found in other eukaryotic regulatory proteins  (Tamkun et al. 
1992). Recognition of acetyl-lysine was thought to be limited to bromo-domains, but more 
recently the  DPF (double PHD finger) domain of human DPF3b, which functions in 
association with the BAF chromatin remodelling complex to initiate gene transcription has 
been associated with binding acetyl marks (Zeng et al. 2010).  
A variety of methylation binding proteins have been described, which is probably due to the 
variety of methyl marks. The chromo-domain of Polycomb and HP1 proteins of Drosophila 
was described as a methyl-binding motif that binds to H3K27me3 (Paro & Hogness 1991). 
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This domain is a member of the ‘royal family’ of domains, a structurally related group of 
folds, which bind methyl groups (Mallette & Richard 2012) and also includes the tudor-
domain and/or the MBT domain. The tudor-domain has been reported to bind to different 
methyl-marks, for example in the SMN protein, which is linked to spinal-muscular atrophy, 
the tudor-domain binds to symmetrically di-methylated arginines (Selenko et al. 2001), 
whereas in the demethylase JMJD2A  the domain binds to methylated H3K4 and H4K20 
(Huang et al. 2006). The MBT (malignant brain tumor) domain can recognize mono- and di-
methylated lysines at various positions on the histone tails. PHD (plant homeo domain) 
fingers (not a tudor domain family member) are found in a variety of different proteins, 
where they interact specifically with H3K4me3 (e. g.  the PHD finger of the chromatin 
remodeller NURF; Wysocka et al. 2006). However, there is some overlap between their 
binding sites as  some domains can recognize the same methylation marks (Bannister & 
Kouzarides 2011).  
Phosphorylation is recognized by the well-conserved 14-3-3 family of phospho-specific 
binding proteins. These are independent dimeric proteins that offer two sites for protein 
binding and  therefore can act as adaptors between phosphorylated histones (H3S10p and 
H3S28p) and the effector protein (Macdonald et al. 2005).  Recently the BIR (Baculovirus IAP 
Repeat) domain of Survivin has been shown to bind to H3T3 phosphorylation 
(Niedzialkowska et al. 2012). 
It has also been described that unmodified histone tails can be recognized by specialized 
PHD fingers and WD40 domains, which would make unmodified histone tails signals in their 
own right. For example the PHD finger of BHC80, a member of the LSD1 demethylase 
complex, binds specifically to H3K4me0 and this interaction is abolished when H3K4 is 
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methylated (Lan et al. 2007). Likewise, the human autoimmune regulator AIRE was also 
shown to interact with the unmodified H3K4  via its PHD fingers (Chakravarty et al. 2009). 
The binding  affinities of binding domains have been shown to be relatively weak, 
which allows rapid ’on-off’ binding (Daniel et al. 2005). Also, binding domains are often 
found in close proximity to each other or contain several copies of a specific reader domain. 
For example, in ING2 a bromo-domain is found next to PHD fingers forming the BPTF 
(bromo-domain and PHD domain transcription factor) domain (Shi et al. 2011). This could 
allow co-binding, which would be expected to  strengthen  the binding of the effector 
protein to chromatin. Furthermore, the combinatorial readout of histone modification can 
modulate and specify the recruitment of reader proteins (Musselman et al. 2012).  
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Figure 1.5: Histone modification binding domains. Histone modifications are recognized by conserved 
binding protein modules, which are highly specific for distinct modifications at specific residues.  Bromo-
domains and DPF domains are known to bind to acetylated residues. Chromo- , Tudor- and MBT domains, 
as well as PHD fingers bind to methyl-marks. Phosphorylated residues are recognized by 14-3-3 proteins. It 
has also been reported that the BIR domain can bind to phospho-marks.   
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1.5 The histone methyltransferase MLL1 
Eukaryotic gene expression is controlled by modification of chromatin structure through the 
enzymatic action of transcriptional regulators. MLL1 modifies chromatin structure by 
regulating the degree of H3K4 methylation (Liedtke & Cleary 2009). As it was first discovered 
about 20 years ago, chromosomal diagnostics of acute lymphoid leukaemia (ALL) and acute 
myeloid leukaemia (AML) patients, showed a recurring chromosomal translocation involving 
chromosome 11, band q23. The gene on this  frequent chromosome break point was 
therefore termed mixed-lineage leukaemia (MLL)  (Ziemin-van der Poel et al. 1991). 
MLL1 is a large protein of 3900 amino-acids, which is cleaved by the Taspase 1 enzyme after 
translation into a 320kDa N-terminus (MLLN) and a 180kDa C-terminus (MLLC), which are 
bound together and form the MLL1 core complex (Yokoyama et al. 2002).  The domain 
structure is complex (Figure 1.6 A). In control of the hetero-dimerization of the MLL1 core 
complex are the FYR-domains on the N- and the C-terminus  (Ansari & Mandal 2010).  MLL1 
also contains multiple domains, which are involved in targeting MLL1 to its target sites. The 
AT-hooks on the N-terminus bind to the minor groove of AT-rich DNA without a specific 
recognition sequence (Zeleznik-Le et al. 1994).  This domain is followed by two subnuclear 
localization signals (SNLs) and further downstream by the methyl-transferase-homology 
(MT) domain, which contains a specialized CxxC region and binds exclusively to non-
methylated CpG islands, a characteristic of transcriptionally active genes (Birke et al. 2002). 
In addition, this region has also been shown to recruit repressing factors, like the polycomb 
repressor proteins HPC2 and BMI1, orthe histone deacetylases HDAC1 and HDAC2 (Xia et al. 
2003). MLL1 also contains reader domains, which bind to modified histones. The PHD-fingers 
bind to methylated lysines and the bromo-domain bind acetylated residues (Daser & 
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Rabbitts 2004). On the C-terminus the TAD and the SET domain can be found. The TAD 
domain is a conserved transcriptional activation domain, which binds to the coactivator CBP 
(Bannister & Kouzarides 1996; Arai et al.  2010). The SET (Suppressor of Variegation, 
Enhancer of Zeste, and Trithorax) domain is responsible for the transcriptional activation and 
holds the HMT activity (Milne et al. 2002; Ruthenburg et al. 2007). SET proteins are highly 
conserved. In Saccharomyces cerevisiae, Set1 is a member of the COMPASS (complex 
proteins associated with Set1) complex, which is essential for the mono, di- and tri-
methylation of histone H3 at lysine4 and therefore the stimulation of transcription in yeast 
(Miller et al. 2001). In  Caenorhabditis elegans,  the SET-1 and SET-2 proteins have been 
identified as nematode counterparts to the yeast SET1 protein (Simonet et al. 2007). In 
Drosophila melanogaster  Trithorax group proteins (TRX, ASH1 and ASH2)  contain SET 
domains  (Petruk et al. 2001), whereas in mammals at least six proteins contain SET 
domains: MLL1, MLL2, MLL3, MLL5, SET1A and SET1B (Wang et al. 2009). After the post-
translational cleavage of MLL1, it is incorporated into a multi-protein complex (Figure 1.6 B). 
The core of the complex consists of MLL1 and the WARD proteins WDR5, Ash2L, RbBP5 and 
DPY-30. The association of these five proteins is sufficient to catalyse the methylation of 
histone 3 (Dharmarajan et al. 2012).  It has been found that RbBP5 is essential to maintain 
mono- and di-methylation of histone H3, whereas Ash2L and DPY-30 are needed for the tri-
methylation.  These proteins are critical for the stability of the MLL1 complex, as in yeast the 
SET1-complex is shown to become unstable when any of the WARD proteins are depleted 
(Ernst & Vakoc 2012).  On the other hand WDR5 can bind H3K4, but does not distinguish 
between its different methylation states. It was therefore thought that WDR5 presents the 
peptide for further methylation to the SET domain (Ruthenburg et al. 2006). The crystal 
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structure of MLL1 with the bound H3K4me3 mark however revealed that this is sterically not 
possible. Moreover WDR5 binding, in contrast to RbBP5 and Ash2L binding, did not stimulate 
methyl-transferase activity (Southall et al. 2009). It was shown that WDR5 binds to a 
conserved arginine containing motif (Win=WDR5 interaction motif) that is essential for the 
assembly of the MLL1 core complex and H3K4 dimethylation activity  (Patel et al. 2008).  
Furthermore, in the complex the acetyl-transferases CBP and MOF can be found. MOF 
specifically acetylates lysine 16 on histone 4, a modification known to relax chromatin 
structure via charge neutralization (Dou et al. 2005). CBP binds to MLL1’s TAD domain and is 
necessary for its  transcriptional activation (Arai et al. 2010). The complex also contains a 
number of proteins involved in targeting. It has been shown that MLL1 recruitment is highly 
dependent on menin (Milne et al. 2005). Later it was found that MLL1 and menin form a 
binding surface for LEDGF, which binds to chromatin via a PWWP domain, a motif 
structurally related to Tudor-/Chromo-domains (Yokoyama & Cleary 2008). The exact 
number of proteins, which are involved in this macromolecular complex it is still unknown 
with numbers ranging between 5 (WARD proteins) and up to 29 protein members 
(Nakamura et al. 2002).  This is probably down to two main reasons. Firstly not all protein 
interactions are stable and it may be that some proteins are only transient members of the 
complex. For example MOF and MLL1 are recruited together (Dou et al. 2005), whereas CBP 
interacts only to activate transcription (Ernst et al. 2001).  Secondly, it may also be that on 
different target sites, different proteins may be involved and/or that these proteins may be 
at the same target site, but not part of the MLL1 complex. In general it can be summarised 
that the MLL complex coordinates three major mechanisms of chromatin biology: 
methylation, acetylation and nucleosome remodelling (Slany 2009).   
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Figure 1.6: MLL domain structure and the MLL complex. (A) MLL1 has a complex domain structure. At the 
extreme end of the N-terminus AT-hooks can be found, next to Subnuclear-location domains, followed by a 
MT domain, with a characteristic CxxC-motif. These domains are involved in the non-specific binding of MLL1 
to the DNA. A PHD-finger cassette for the recognition of methylated lysines and a bromo-domain for binding 
to acetylated histones are located at the N-terminus.  On the C-terminus the SET domain is found, which holds 
the methyl-transferase activity.  After translation the protein is cleaved by the Taspase1 enzyme at its 
cleavage site. The FYRN and FYRC domains are needed for the association of the two termini. In MLL fusion 
proteins the MLL1 protein breaks at a specific site and the truncated N-terminus is fused to a partner protein.  
Lower panel indicates a MLL-fusion protein, where the MLL1 protein is fused to one of  ~70 partner proteins. 
(B) MLL1 is a large protein, which is cleaved into two fragments (MLL
C
 and MLL
N
). They are bound tightly 
together, associate with a cohort of other proteins and form a multi-protein complex. These proteins can be 
involved in targeting (Menin, LEDGF), histone acetylation (CBP, MOF) or methylation (WDR5, RbBP5, Ash2L, 
DPY-30). 
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1.6 MLL1 in leukaemia 
The MLL1 (mixed lineage leukaemia) gene is located on the long arm  of chromosome 11, at  
locus 11q23, which is associated with aggressive types of leukaemia (Kaneko et al. 1982).  
Abnormalities of the MLL1 gene are found in ~70% of infant leukaemia and in ~10% of adult 
acute myeloid leukaemia (AML) (Felix 1998; Krivtsov & Armstrong 2007). Although the 
overall cure rate of children with leukaemia is good (78-85% at 5 years after the completion 
of therapy), the prognosis for leukaemia with MLL1 rearrangements is poor with an 
approximate cure rate of 20%  (Slany 2005; Brassesco et al. 2009).   
So far three mechanisms are known by which abnormalities at this location can transform 
MLL1 into an onco-protein. The most common mechanism is a balanced translocation that 
leads to the formation of fusion-proteins (see Figure 1.6 A). To date, nearly 100 different 
chromosome rearrangements have been described involving 11q23 and ~70 fusion-proteins 
have been characterized. These translocations seem to appear in utero, but it is unknown 
why chromosome 11 tends to break in this restricted 8.3 kb region (Ford 1993; Sim & Liu 
2001).  However, only five translocations occur in more than 66% of clinical cases with MLL 
rearrangements (MLL-AF4, MLL-AF9, MLL-AF10, MLL-ENL and MLL-ELL; Brassesco et al. 
2009).  The fusion-proteins share (with some exceptions) a common protein structure, in 
which only a small part of the N-terminus is conserved and fused together with the partner 
protein  (Zhang et al. 2012). Less common transformations of the MLL1 gene are internal 
tandem duplications within the MLL coding region or amplification of the unaltered MLL1 
gene itself (Basecke et al. 2006).  
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All fusion-proteins lose the C-terminus with the SET domain, which leads to a loss of H3K4 
methylation and one would expect a decrease of target gene expression. However, the 
fusion partners induce transcriptional activity at MLL1 target genes, which leads to a gain of 
function and therefore they are crucial for leukaemogenesis (Dharmarajan & Cosgrove 
2009). Despite the vast numbers of fusion partner proteins, according to Slany, only four 
molecular pathways lead to the oncogenic activation of MLL1 target genes (Slany 2009). (I) 
The most frequent fusion partners (eg MLL-AF4 and MLL-ENL) interact with the EAP 
complex. In this complex DOT1L, a histone H3K79 methyl-transferase, and pTEFb, which 
phosphorylates the C-terminal repeat domain of RNA polymerase II, can be found. (II) Fusion 
partners can be histone acetyltransferases (e.g. MLL-CBP or MLL-EP300) or (III) can bring 
additional methyl-transferase activity (eg MLL-EEN) to the target loci.  (IV) It was also shown, 
that fusion partners supply dimerization domains, which leads to the dimerization of MLL1 
and gene activation by unknown mechanisms (Slany 2009). 
Although the mechanisms may vary, a hallmark of all MLL1 associated leukaemias is the 
irregular expression of MLL1 target genes.  Especially HoxA7 and HoxA9 have been reported 
to be essential for the transformation of myeloid progenitors (Ayton & Cleary 2003). It was 
also shown that besides the up-regulation of these Hox genes, the up-regulation of the Hox  
cofactor Meis1 plays an important role in leukaemogenesis (Zeisig et al. 2004). 
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1.7 MLL1 targets the Hox genes 
MLL1 is an essential protein. Knock-out studies in mice show, that MLL-/- embryos die at 
embryonic day 10.5.  Embryonic lethality is accompanied by retarded growth, 
haematopoietic abnormalities and homeotic transformations of the axial skeleton (Yu et al. 
1995; Yu et al. 1998). It was found that MLL1 is required for the maintenance of normal 
numbers of haematopoietic progenitors and their proper differentiation (Hess et al. 1997). 
These changes were accompanied by altered Hox gene expression and altered levels of 
histone methylation (Terranova et al. 2006). Later it was shown that in the adult, MLL1 also 
maintains haematopoietic stem cells and progenitors (Jude et al. 2007).  Moreover, MLL 
regulates Hox gene expression through direct binding to promoter sequences  (Milne et al. 
2002) and by maintaining Hox gene expression, induces proliferation and differentiation of 
haematopoietic progenitors (Argiropoulos & Humphries 2007). 
The Hox genes encode homeodomain transcription factors, which are critical for the proper 
establishment of regional identities in developing organisms. First discovered in D. 
melanogaster, mutations in the homeotic genes were found to lead to the developmental 
replacement of one body part  by another (Frischer et al. 1986). They are highly conserved 
and in many species are grouped into genomic clusters with a similar organization. As shown 
in Figure 1.7 A, the single Hox gene cluster in fly was multiplied through subsequent gene 
duplication and in vertebrates four paralogous Hox clusters (Hox A, B, C and D) are found 
(Holland 2013).   
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As shown in Figure 1.7 B, the Hox genes are uniquely regulated as a result of their genomic 
organization. Their gene activity depends on their position in the cluster, what is known as 
‘collinearity’ (Lewis 1978; Graham et al. 1989). This can take two forms. Firstly, the Hox 
genes, which are located at the 3’ end of the cluster, tend to be expressed in more anterior 
regions of the organism, whereas genes at the 5’ are expressed in the posterior region. This 
association between the position of the Hox gene in the cluster and its expression in the 
organism is referred to as spatial collinearity (Gaunt et al. 1988). Secondly, genes at the 3’ 
are activated first and progressively the other Hox genes follow, according to their 
consecutive position in the cluster, which is known as temporal collinearity (Izpisua-
Belmonte et al. 1991). Spatial and temporal regulation of the Hox genes occurs in parallel, 
which led to the hypothesis that Hox gene clustering is essential for coordinating the varied 
timing of gene activation. However, studies in mutant mice, in which the HoxD cluster was 
mutated, showed no systematic impact upon subsequent expression patterns, suggesting 
the spatial and temporal regulatory mechanisms could be uncoupled (Tschopp et al. 2009). 
Chromatin plays an important role in the activation of the Hox genes (Figure 1.7 B). In 
the early mouse embryo the Hox genes are transcriptionally inactive and their chromatin is 
heavily marked with H3K27me3. Around day 8.5 the 3’ end of the Hox cluster becomes 
active and the chromatin is marked with H3K4me3. As activation of the Hox genes 
progresses, more and more of the H3K27me3 marks are replaced with H3K4me3. By day 9.5 
the whole cluster is transcriptionally active and covered with H3K4me3 (Montavon & 
Soshnikova 2014). 
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Figure 1.7: Hox genes in fly, mouse and human. (A) In mouse and human 39 Hox genes are found in four 
clusters of Hox A, B, C and D on different chromosomes. Marked in grey are the paralogue genes and their 
corresponding genes in D. Melanogaster. The order of the Hox genes on the chromosome corresponds to 
the order of the body parts that are controlled by them: genes at the 3’ position of the chromosome are 
expressed in anterior body structures whereas the genes in 5’ positons are expressed in posterior body 
structures. Furthermore, Hox genes are expressed in a progressive way, starting with the 3’ genes 
expressed first advancing towards the 5’, which are expressed last (Pang & Thompson 2011). (B) This 
expression is accompanied by changes in chromatin structure. In an inactive state, the whole cluster is 
labelled with H3K27me3, bit upon Hox gene activation they are marked with H3K4me3 (Montavon & 
Soshnikova 2014). 
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1.8 MLL1 in the context of histone modifications 
In general Hox genes are regulated by the Polycomb and Trithorax protein complexes, which 
are highly conserved and work as antagonistic partners in gene expression (Schuettengruber 
et al. 2007).  Although their first and best characterized targets are the Hox genes, they also 
regulate many other genes. Polycomb and Trithorax proteins bind to many more loci making 
them epigenetic master regulators, which have an regulatory impact on cell-cycle control, 
tissue growth and cell proliferation (Zink & Paro 1989; Schumacher & Magnuson 1997; 
Mendenhall & Bernstein 2008; Christophersen & Helin 2010; Kolybaba & Classen 2014).  
Polycomb and Trithorax proteins act as member of large protein complexes, which act 
primarily by depositing or reading, histone modifications like histone methylation, 
ubiquitylation and acetylation. Polycomb proteins repress, while Trithorax proteins activate 
transcription (Klymenko & Müller 2004). For example, tri-methylation of lysine 27 on histone 
3 (H3K27me3) is deposited by PRC2 (polycomb repressive complex 2) and is associated with 
gene silencing (Schwartz et al. 2006), whereas tri-methylation of lysine 4 on histone 3 
(H3K4me3) is deposited by SET proteins and activates gene  expression,  antagonizing 
Polycomb-induced silencing (Tie et al. 2014). In summary the activating and silencing of 
Trithorax and Polycomb proteins is tightly coupled and balanced (Steffen & Ringrose 2014). 
Both Polycomb and Trithorax proteins deposit methyl-marks on chromatin, which requires 
close teamwork with demethylases in order to remove the opposing methyl-mark before 
deposition of a new mark. For example, whereas the UTX and the JMJD3 H3K27 
demethylases are essential for proper development, UTX also associates with the H3K4me3 
histone methyl-transferase MLL2 (Agger et al. 2007). Lid (Little imaginal discs), a jumonji C 
domain-containing protein with trimethyl H3K4 demethylating activity  was shown to 
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reverse TRX-mediated methylation in Drosophila (Eissenberg et al. 2007). In humans 
JARID1d, another jumonji C-domain-containing protein was found to specifically 
demethylate trimethyl H3K4 and interacts with a Polycomb-like protein (Ring6a/MBLR) to 
bind to chromatin (Lee et al. 2007). 
In mammals MLL1 is one member of the Trithorax protein family, which  depoosits the 
H3K4me3 mark. This makes H3K4me3 and H3K27me3 key histone modifications at MLL1 
target sites (Canaani et al. 2004). In vitro studies with a recombinant MLL1 SET domain found 
that the methyl-transferase activity was stimulated by acetyl- and phospho-marks on the 
same histone (H3K9ac and H3S10p). The effect was biggest when both marks were on the 
histone at the same time, as a phosphoacetyl-mark (H3K9ac-S10p; Nightingale et al. 2007). 
In contrast, two different studies showed the phosphorylation of serine28 on histone 3 
(H3S28p) antagonizes Polycomb protein 2 (PRC2)-mediated silencing and activates target 
genes. This suggests that histone phosphorylation may play a functional role in regulating  
TRX and PCG action. In both studies the phosphorylation mark was deposited by Msk1 
(Gehani et al. 2010; Lau & Cheung 2011).   
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1.9 Msk1 
Msk1 (mitogen–and-stress-activated kinase 1) is a 90 kDA protein, which was described first 
in 1998 as a downstream target of the MAPK (mitogen-activated-protein-kinase) pathways 
(Deak et al. 1998). MAPK are serine-threonine kinases that can react to a range of different 
stimuli on the cell surface and act by consecutive cascade-phosphorylation of downstream 
targets in the cytoplasm and the nucleus  (Edmunds & Mahadevan 2004). In mammals four 
MAPKs are known: ERK (extracellular regulated kinase) 1/2 and 5 and p38. These proteins 
are essential regulators for many regulatory processes, including those on the DNA (Klein et 
al. 2013). Msk1 is a downstream target of the ERK1/2 or the p38 pathway and is universally 
expressed in cells and found in mammals, nematode and fly, but not in yeast or plant (Hauge 
& Frödin 2006).   
Thus far Msk1 and its homologue Msk2 have only one well-established function. As shown in 
Figure 1.8, they regulate gene expression by phosphorylation of either transcription factors 
or histones (Vermeulen et al. 2009). For example, Msk1 and Msk2 are required for the 
phosphorylation of the transcription factors CREB and ATF1. Without this phosphorylation 
CREB and ATF1 cannot properly activate their target genes (Wiggin et al. 2002). Another 
transcription factor targeted by Msk1 is NFκB, which is involved in the immune and 
inflammatory response. Msk1 phosphorylation of NFκB is essential for its transactivation 
capacity (Vermeulen et al. 2003).  Msk1 can phosphorylate histone H3 at serine 28 or serine 
10, however the two marks are not found on one histone tail together and Msk1 does not 
have an intrinsic specificity for one residue, suggesting that Msk1 kinase activity is context-
dependent, potentially reflecting its genomic location (Arthur 2008). Thus far no consensus 
phosphorylation motif has been identified. It is likely that Msk1 cooperates with other 
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proteins, so that only a single site (i.e. S28 or S10) is available for phosphorylation. 
Alternatively the interaction  with partner proteins may modulate Msk1’s substrate 
specificity (Dyson et al. 2005).  
Msk1 is transcribed at basal levels in the cell but kept in an inactivated, non-phosphorylated 
state. After the binding of either ERK1/2 or p38 at the MAPK docking site, the linker and the 
CTK (C-terminal kinase) domain is phosphorylated. The CTK domain auto-phosphorylates the 
rest of the linker domain and the NTK (N-terminal kinase), which leads to an allosteric 
change that activates the NTK domain (Msk1 domain structure and phosphorylation sites are 
shown in Figure 1.9 A). This conformational change leads to a rapid 10-50 fold increase of 
Msk1 activity in the cell (McCoy et al. 2005).  However, how Msk1 is inactivated and whether 
this is coupled to the MAPK pathway is not clear. Thus far no phosphatase that might 
inactivate Msk1 has been identified  (Duda, 2012). 
Besides Msk1 there is one homologue in humans, Msk2. Msk1 and Msk2 share about 76% 
protein identity. The core sequence of Msk1 and Msk2 are essentially the same. As shown in 
Figure 1.9 B  Msk2 lacks the extreme N-terminus (amino acids 1-16) and the extreme C-
terminus (amino acids 574-805) of Msk1 (Blast, Basic local alignment search tool).  
Functionally, only a few differences between Msk1 and Msk2 have been observed. It seems 
that in cells where both homologues are present, they show only minor differences in 
substrate choice, though Msk1 has a shorter activity period after  activation (~30 min) than 
Msk2 (~3 hours) (Duda, 2012). 
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Figure 1.8: Msk1 is a downstream target of the MAPK signalling pathway. In humans four MAPK pathways are 
known, but only two activate Msk1 and its homologue Msk2. A variety of different stimuli at the cell surface 
activate the intra-cellular phosphorylation cascade, which leads to the activation of Msk1/2 in the nucleus.  
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Figure 1.9: Msk1 domain structure and comparison to Msk2. (A) Msk1 is constantly expressed in cells and 
kept in an un-phosphorylated, inactive state. Upstream kinases have to bind to the MAPK docking site and 
activate the C-terminal kinase, which then auto-phosphorylates Msk1 (Phosphorylation sites are indicated 
with blue circles and P).  This activates the N-terminal kinase, which then auto-phosphorylates its tail 
domain for full activation and Msk1 targets (adapted from Duda, 2012). (B) Msk1 and Msk2 show 76% 
sequence identity (BLAST result, visualised with Jalview software: regions of high sequence identity are 
shown in red, those of low identity in orange).  The core sequence of Msk1 and Msk2 are similar, but Msk2 
is shorter than Msk1. The extreme N-terminus (AA 1-18) and the extreme C-terminus of Msk1 (AA 574-802) 
are not present in Msk2. The scissor-symbol in (A) indicates the missing termini, showing that the core-
domain structure is conserved. 
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1.10 Aims 
It is now well established that there is a close link between the chromatin state and the 
activity of genes. Histone modifications provide a layer of epigenetic information that can 
determine the functional state of chromatin. These are deposited by specific chromatin 
modifying enzymes, but also can modulate the activity or the binding of these enzymes. This 
results in a close interaction and inter-dependence between histone modifications and 
chromatin modifying enzymes, providing a network of regulatory information, which can 
integrate information from outside and inside the cell. MLL1 is a conserved histone methyl-
transferase, which deposits H3K4me3, a key regulatory mark in gene expression. This 
complex integrates histone methylation and acetylation, making it a powerful regulator of 
gene activity. Data from our laboratory has previously shown that MLL1’s SET MTase activity 
is stimulated by histone 3 phospho-acetylation (H3K9ac/S10p; Nightingale et al. 2007). 
Acetyl-transferases are members in the MLL1 complex and acetylation is closely linked to 
active genes, however, to date no histone kinase has been associated with MLL1. In 
mammalian cells, two chromatin-associated histone kinases are known, Msk1 and Msk2, to 
play a role in PCG regulation.  
We therefore hypothesized that Msk1 is involved in the regulation of the MLL1 complex. In 
this thesis I explore the nature of the MLL1 and Msk1 interaction and the functional 
implication of this. To investigate the nature of this interaction we examined the 
components of the MLL1 complex and characterize complex subunits. We also set out to 
explore the distribution of MLL1 and Msk1 in vivo and identify genes that were regulated by 
these proteins.  Finally we examined the function of MLL1 and Msk1 through the cell cycle to 
gain a greater understanding of the regulation of MLL1 in a physiological context. 
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2 Materials and Methods 
2.1 Tissue Culture 
2.1.1 Cultivation of mouse embryonic fibroblasts (MEFs) 
Mouse embryonic fibroblasts (MEFs) are a widely used ‘primary’ cell-line (Smith 2001). Here 
MEFs were isolated from Balb/c wild-type mouse embryos between day 12 – 15 of gestation. 
Normally five E15 embryos were processed at a time. They were isolated, the heads and 
inner red organs removed and then the tissue dispersed in 10ml of 0.05% trypsin-EDTA 
(Gibco). The embryos were minced for ~2 min with a scalpel and then incubated for 20 min 
at 37°C. 10ml of culture medium [DMEM (Gibco), 1/100 penicillin (10000 U/ml, Gibco), 
1/100 streptomycin (10000 U/ml, Gibco), 1/100 L-glutamine (200mM, Invitrogen), 1/100 
MEM non-essential amino acids, Gibco), 1/1000 2-mercaptoethanol (Gibco), 10% v/v foetal 
calf serum (Invitrogen)] was then added and a single cell suspension was generated by 
pipetting vigorously for ~2 min. 8ml of the cell suspension was aliquoted into a 150cm2 flask 
with 20ml MEF Growth Medium, which was passage 1. Cells were incubated at 37°C and 5% 
CO2, and depending on their density were divided 1:4 every 3
rd day. Only cells between 
passage 2 and 4 were used.  
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2.1.2 Cultivation of LCL cells 
LCLs are a human lymphoblastoid cell line with a normal karyotype, which are routinely used 
for karyotyping (Terrenoire et al. 2010). The cells were grown in RPMI medium [RPMI 1640 
(Gibco), 1/100 penicillin (10000 U/ml, Gibco), 1/100 streptomycin (10000 U/ml, Gibco), 
1/100 L-glutamine (200mM, Invitrogen), 10% v/v foetal calf serum (Invitrogen)]. After three 
to four days, dependent on their density, the cells were divided 1:5 and incubated in fresh 
medium at 37° C and 5% CO2. 
 
2.1.3 Cultivation of SL2 cells 
Drosophila SL2 (Schneider line-2) is a cell line, which was isolated from late embryonic stages 
of Drosophila (Schneider 1972). The cells were cultured in Schneider’s medium [Insect 
Xpress (Lonza), 5% v/v foetal bovine serum (Invitrogen), 1/100 penicillin (10000 U/ml, 
Gibco), 1/100 streptomycin (10000 U/ml, Gibco)]. The cells were incubated at 26°C and 
divided every 5 days 1:10. 
 
2.1.4 Cultivation of HEKs 
Human embryonic kidney cells (HEKs) were generated by the transformation of embryonic 
kidney tissue with the SV-40 virus (Sheint & Enders 1962) and later with the adenovirus type 
12 (Zur Hausen 1967). The cells were cultured in DMEM [DMEM (Gibco), 1/100 penicillin 
(10000 U/ml, Gibco), 1/100 streptomycin (10000 U/ml, Gibco), 1/100 L-glutamine (200mM, 
Invitrogen), 10% v/v foetal calf serum (Invitrogen)]. Every 4 days the cells were divided 1:10 
and incubated in fresh medium at 37°C at 5% CO2. 
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2.2 Transfection methods 
2.2.1 Amplification of transfection vectors 
Three transfection vectors were used: Msk1 knock-down vector (Figure 2.1 A, Origene 
TR504795), MLL1 knock-down vector (Origene, TR517798) and a flag-tagged MLL1 (Figure 
2.1 B, pMSCVneo, supplied from R. Slany, University of Erlangen). Vector DNA needed to be 
amplified and was therefore introduced into E.coli (α-select gold efficiency, Bioline). Vector 
DNA (~20ng) was mixed with 50 μl of E.coli and incubated on ice for 30 minutes prior to a 30 
second heat-shock at 42°C. The bacteria were subsequently cultured in 1 ml LB [1% w/v 
tryptone, 0.5% w/v yeast extract, 1% w/v NaCl] without antibiotics for 1 hour and then 
plated on a LB-plate [1% w/v tryptone, 0.5% w/v yeast extract, 1% w/v NaCl, 1.5% w/v Agar] 
with added ampicillin (final concentration 100 μg/ml, Sigma) and incubated overnight at 
37°C. The next day an isolated clone was picked and cultured in 5ml of LB with added 
ampicillin (final concentration 100μg/ml) and cultured at 37°C with shaking over the day. In the 
evening 500ml of LB medium with ampicillin (final concentration 100μg/ml) were inoculated 
with the day culture and incubated overnight at 37°C with shaking. The next morning the 
bacteria were collected by centrifugation (4000g, 10 minutes, 4°C) and the plasmid DNA 
purified using the GeneElute Plasmid MaxiPrep Kit (Sigma) according to the manufacturer’s 
instructions. 
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Figure 2.1: Vector maps. The maps for the vectors used for transfection are shown. (A)  The pRS vector with 
a shRNA target sequence for either MLL1 or Msk1 knock-down (Origene) is shown. (B) The pMSCVneo 
Vector, which carried the Flag-MLL cDNA is shown.  
A 
B 
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2.2.2 Transfection of MEFs 
MEFs were used to examine the effect of MLL1 and Msk1 knock-downs. For one transfection 
4x106 MEFs were harvested with trypsin and collected by centrifugation (300g, 5 minutes, 
RT), before washing them twice with PBS [phosphate-buffered saline: 1.37M NaCl, 27mM 
KCl, 100mM Na2HPO4, 18mM KH2PO4]. The cells were resuspended in 400μl of transfection 
buffer [10mM HEPES, pH7.5, 135mM KCl, 2mM MgCl2, 5mM EGTA, 25% FBS] and 20μg of 
knock-down vector DNA were added. The cell suspension was transferred into 0.4cm 
cuvettes (BioRAD, Cat# 1652088) and electroporated (300V, 950μF, 1000Ω, BioRad 
GenePulser XCell) prior to being transferred into a 10cm dish with 10ml of MEF growth 
medium and incubated at 37°C and 5% CO2 for 5 hours. Puromycin (Gibco, final 
concentration 10 μg/ml) was added to select for transfected cells and the cells were 
incubated again at 37°C and 5% CO2. MEFs were harvested after a total of 20 hours post-
transfection. 
2.2.3 Transfection of HEKs 
HEKs were used for the expression of FLAG-MLL1 protein and therefore transfected with the 
pMSCV-FLAG-MLL1 vector (Figure2.1). The day before transfection the cells were divided 
and seeded at a density of 4x106 cells per 10cm dish in complete medium [DMEM (Gibco), 
1/100 penicillin (10000 U/ml, Gibco), 1/100 streptomycin (10000 U/ml, Gibco), 1/100 L-
glutamine (200mM, Invitrogen), 10% v/v foetal calf serum (Invitrogen)]. The next day, a mix 
of 15μg vector DNA, 1000μl OptiMEM media (Gibco) and 60μl of Polyethyleneimine (1mg/ml 
stock solution, Polyscience Inc.) per plate was made up, vortexed thoroughly, incubated at 
room temperature for 30 minutes and added drop-wise to the plates.  The cells were 
cultured at 37°C at 5% CO2 for 3 days and then harvested.  
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2.3 Protein Methods 
2.3.1 Preparation of whole cell extract 
Cells were collected and washed three times with ice-cold PBS before the cell pellet was 
resuspended in 500μl lysis buffer [10mM Tris, pH 7.9, 150mM NaCl, 5mM EDTA, 0.5mM 
EGTA, 1mM β-mercaptoethanol, 1% v/v NP40, 25% v/v glycerol]. The cell suspension was left 
on a rotating wheel at 4°C for 30 minutes, before sonicating at high amplitude for one 
minute (Bioruptor, Diagenode). The suspension was then centrifuged at 13000 rpm for 10 
minutes at 4°C, and the supernatant stored at -20°C. 
 
2.3.2 Isolation of histones 
Cells were collected and washed twice with cold PBS, to which 10mM sodium butyrate was 
added. Cells were resuspended in Triton extraction buffer [TEB: 1xPBS, 4mM sodium 
butyrate, 0.5% v/v Trition X-100, 2mM PMSF, 0.02% v/v sodium azide] to a final 
concentration of 107 cells per ml and left on ice for 10 minutes, before centrifuging for 10 
minutes at 2000 rpm at 4°C. The pellet was resuspended in half the volume of TEB and 
centrifuged again at 2000 rpm for 10 minutes at 4°C. The pellet was then resuspended in 0.4 
M HCl at a concentration of 4x107 cells per ml and left on ice for 3 hours at 4°C. After 
centrifugation to pellet the nuclear debris, the supernatant with the solubilized histones was 
removed and stored at -20°C. 
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2.3.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated according to size following the method developed by Laemmli 
(Laemmli, 1970). Samples were loaded on an acrylamide gel, with a concentration 
dependent on the size of the proteins to be separated. Generally 50μg of whole-cell extract 
or 10μg of purified protein was loaded. For the detection of Msk1 (~90kDa MW) and Actin 
(~50kDa MW) a 10% SDS gel [10ml Acrylamide (30%  Acrylamide - 0.8%  Bis), 7.5ml 1.5mM 
Tris, pH 8.8, 300μl 10% w/v SDS, 100μl 10% w/v ammonium persulfate, 30μl TEMED, made 
up to a total volume of 30ml with distilled water]  was prepared. For MLL1 (~300 kDa MW) a 
4% gel was prepared. The resolving gel was overlaid with 100% isopropanol to prevent 
evaporation during polymerisation. This was washed away before the addition of the 
stacking gel [1ml Bis-acrylamide (30% Acrylamide-1.6% Bis), 6.3ml 0.5mM Tris, pH 6.8,  100μl 
10%  w/v SDS, 100μl 10% w/v ammonium persulfate, 10μl TEMED, made up to a volume of 
10ml with distilled water]. Protein samples were resuspended in 10xloading buffer [20% 
SDS, 500mM Tris, pH 7.6, 50% v/v glycerol, 1M DTT, 1mg/ml bromophenol blue], incubated 
at 95°C for 10 minutes and loaded onto the gel through SDS reservoir buffer [50mM Tris, 
0.384M glycine, 0.1% v/v  SDS]. The gel was electophoresed at constant 60mA, for 3 hours in 
a standard vertical electrophoresis unit (Hoefer “SE 600 Ruby”, GE Healthcare) 
 
2.2.4 Staining protein gels 
To visualise proteins in SDS gels they were stained either with Coomassie blue or with silver-
nitrate. For Coomassie blue staining the gel was soaked in Coomassie-solution [1.25% w/v 
Coomassie Brilliant Blue R250 (Sigma), 10% v/v isopropanol, 30% v/v methanol, 10% v/v 
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acetic acid] for 30 minutes. The background was removed by soaking the gel in Destain-
Solution [30% v/v methanol, 10% v/v acetic acid] until only the protein bands were visible.  
For silver staining the gel was soaked overnight in 50% v/v methanol to fix the proteins. For 
the staining solution, Solution A [0.8g Silver nitrate, 2ml distilled water] and Solution B 
[10.5ml 0.36% w/v NaOH, 800μl 14.2M NH4OH] were prepared independently, slowly mixed 
together with constant stirring and finally made up to 50ml with  distilled water. The gel was 
soaked for 15 minutes in the Staining solution and then washed with distilled water for 15 
minutes. The gel was then soaked in the Developing solution [2.5ml 1% w/v citric acid, 50μl 
38% formaldehyde, made up to 500ml  with distilled water] until the protein  bands were 
visible. The reaction was stopped by adding Stopping solution [45% v/v Methanol, 10% v/v 
acetic acid].  
 
2.3.5 Immuno-detection of proteins on nitrocellulose membranes  
Western blotting was performed according to a standard protocol (Towbin et al., 1979). 
Briefly, the separated proteins were transferred  onto a Hybond-C nitrocellulose membrane 
(Amersham) in a Trans-Blot Cell (BioRAD) for three hours (180V, 300mA, 20W) using transfer 
buffer [25mM Tris, 192mM glycine, 20% v/v methanol]. The efficiency of the transfer was 
checked by Ponceau Red (Sigma) staining. The membrane was then incubated for one hour 
at 4°C in blocking buffer [10% w/v dried milk powder, 1xTBS (50mM Tris, pH 7.5, 150mM 
NaCl)]. Primary antibodies were either generated in house or obtained from commercial 
sources (listed below). The membrane was then incubated with the primary antibody diluted 
in blocking buffer at room temperature at the recommended dilution. The membrane was 
typically washed three times, each for 10 minutes, with TBS-T [1xTBS (50mM Tris, pH 7.5, 
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150mM NaCl), 0.1% v/v Tween-20]. The secondary antibody was then added in blocking 
buffer and incubated for one hour at room temperature. The membrane was washed three 
times, each for 10 minutes, with TBS-T. Binding was visualised by using the “Odyssey” (LiCor) 
imaging system, which activates the fluorochrome coupled to the secondary antibody 
(LiCor). 
Antibody Source Dilution/Animal 
Msk1-p Abcam ab81294 1:500 / rabbit 
Msk1-p Abcam ab32190 1:500  / rabbit 
Msk1 Bethyl A302-747A 1:500 / rabbit 
MLLC Millipore  05-765 1:500 / mouse 
MLLN Millipore 05-764 1:500 / mouse 
Msk2 R&D systems MAB2310 1:100 / rat 
Actin Abcam ab1801 1:1000  / rabbit 
Pol II Abcam ab5408  1:1000 / mouse 
NFκB Abcam ab7970 1:1000 / rabbit 
Histone H3K4me3 In house R612 1:500 / rabbit 
Histone H3K9ac In house R607 1:500 / rabbit 
Histone H3K27me3 Millipore 07-449  1:1000 / rabbit 
Histone H3S10p Abcam ab32107 1:2500 / rabbit 
Histone H3K9acS10p Abcam ab12181 1:1000 / rabbit 
Histone H3, C-terminal Abcam ab1791 1:2500 / rabbit 
Licor 2nd,  α-rabbit IgG Rockland  611-131-121 1:5000 / goat 
Licor 2nd,  α-mouse IgG Rockland  610-131-121 1:5000 / goat 
AlexaFluor647 2nd, α-rat IgG Life technologies A-21247 1:500/ goat 
Table 2.1: Antibodies used for Western analysis, including commercial source and used dilutions 
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2.4 Functional analysis 
2.4.1 RNA extraction  
Total RNA was isolated from cells using QIAGEN Kits (RNase free DNase Set and RNeasy 
Minikit) according to the manufacturer’s instructions. RNA was quantified using a Implen 
Nanophotometer and stored at -80°C. 
 
2.4.2 Quantitative PCR (qPCR) 
For CChIP analysis, qPCRs was performed with the primers in Table 2.2. “SensiMix SYBR Hi-
Rox” (Bioline) was used. For one reaction 0.25μg of the forward and reverse primers were 
added to 15ng of DNA and 20μl of master mix. PCR samples were pipetted in a 384-well 
optical reaction plate (Applied Biosystems) and loaded into a 7900 HT machine (Applied 
Biosystems). The programme was set up as following: samples were heated at 95°C (15 
minutes), then at 95°C (30 seconds), at 58 °C (30 seconds) and at 72°C (30 seconds). The last 
three steps were performed 40 times.  In order to evaluate primer specificity, a dissociation 
curve was created after each run. qPCR results were analysed by calculating the relative 
expression (2-ΔCt) of the bound fraction compared to the unbound fraction of the same 
CChIP. 
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Gene Name Forward  Reverse  TM 
HoxA4-1   gccgttgttctatcctgctc tgatgcctcactcgtacctg 58°C 
HoxA4-2 agaggcctaggacagacgtg tggatgctgctagccttcag 58°C 
HoxA4-3 tgttggaaggaagccagact aaaatcccccaaactgctct 58°C 
HoxA5-1 atcggctctggctactgaaa agtcgctcccaagctgtaaa 58°C 
HoxA5-2 agccggggaaataaagttgt ggggtcgaattgaggttaca 58°C 
HoxA5-3 gcaagctgctctttctgctt cttctggcctgaggtttctg 58°C 
Table 2.2:  qPCR primer sets for CChIP analysis 
 
2.4.3 Reverse Transcription quantitative PCR (RT-qPCR)  
This method allowed simultaneous RNA reverse transcription and cDNA amplification in one 
step and was performed according to the manufacturer’s instructions. It was used to analyse 
gene expression changes in knock-down cells. The reaction was achieved with commercial 
primers (see table 2.3) and the “Verso 1-step qPCR Syber green mix” (Thermo Scientific). For 
one reaction 0.1μl of enzyme-mix, 5μl of Syber buffer, 0.5μl of RT-enhancer, 1μl of oligos 
and 25ng RNA template were mixed and water added to make up to 10μl. Reactions were 
pipetted in a 384-well optical reaction plate (Applied Biosystems) and loaded into a 7900 HT 
machine (Applied Biosystems). The programme was set up as following: samples were 
heated at 50°C (15 minutes), then at 95°C (15 minutes),  at 95°C (15 seconds), at 58°C (30 
seconds) and at 72°C (30 seconds). The last three steps were performed 40 times. RT-qPCR 
results were analysed by normalizing the expression of genes in knock-down cells to the 
expression of the same genes in control cells (ΔCt). The relative expression of genes was 
calculated by comparing them to the reference gene expression of Actin (2-ΔΔCt). 
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Gene Qiagen primer  Gene Qiagen primer 
β-Actin QT01136772  HoxA7 QT00168707 
Msk1 (Rps6ka5) QT00141554  HoxA9 QT00108885 
Msk2 (Rps6ka4) QT00116760  HoxA10 QT00240212 
Meis1 QT00172557  HoxA11 QT00250404 
HoxA1 QT00248322  HoxA13 QT0027642 
HoxA2 QT0062812  MLL1 QT00240954 
HoxA3 QT00138264  MLL2 QT01075620 
HoxA4 QT00174986  MLL3 QT00310527 
HoxA5 QT00098819  MLL5 QT00279426 
HoxA6 QT00140742    
Table 2.3: Commercial primers used for RT-qPCR 
 
 
2.4.4 Formaldehyde Cross-linking Chromatin Immunoprecipitation (XChIP) 
XChIP was use to define the distribution of MLL1 and Msk1 binding in the genome. For one 
IP 5x106 MEFs were trypsinized (0.05% Trypsin-EDTA, Gibco) and brought into a single-cell 
suspension. The cells were resuspended into MEF growth medium at a final concentration of 
106 cells per ml. The proteins were cross-linked to the DNA by adding formaldehyde drop 
wise to a final concentration of 1% v/v, and incubated at room temperature with gentle 
agitation for 10 minutes. The reaction was stopped by adding 1/10 volume of 2M glycine in 
PBS [137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4] and the cells subsequently 
pelleted by centrifugation for 5 minutes at 300g at 4°C and washed twice with cold PBS. The 
cells were then resuspended in Lysis buffer [1% w/v SDS, 10mM EDTA, 50mM Tris pH 8, 
Protease Inhibitor cocktail (Roche)] to a final concentration of 107 cells per ml and sonicated 
to fragment the chromatin (high power, 30 seconds ON/OFF, 7 cycles, Bioruptor Diagenode). 
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A 100μl input sample was taken to assess the quality of the chromatin.  20μl of Proteinase K 
(20mg/ml) was added to the chromatin and crosslinking reversed by incubation at 65°C for 4 
hours. The DNA was loaded on a 1% agarose gel to verify the size distribution (ideally ~200-
300 bp). The remaining chromatin was diluted 1:2 in Dilution buffer [1% v/v Triton X-100, 
2mM EDTA, 150mM NaCl, 20mM Tris pH 8, protein inhibitor cocktail (Roche)] and IgG coated 
magnetic beads (Thermo Scientific) prepared. For a single immuno-precipitation 15μl of 
beads were washed with citrate-phosphate buffer [CP buffer: 0.47% w/v citric acid, 0.92% 
w/v Na2HPO4] and finally resuspended in 20μl CP buffer with 0.5% w/v BSA. Then 4μg of 
antibody against the desired target protein was added to the beads and rotated for 2 hours 
at 4°C. The beads were then washed with CP buffer and resuspended in 15μl of CP buffer 
with 0.5% w/v BSA, before adding the beads to the quality controlled chromatin. The 
chromatin-beads suspension was rotated for 4 hours at 4°C. The beads were then washed 
twice with low salt buffer [1% v/v Triton X-100, 0.1% w/v SDS, 2mM EDTA, 150mM NaCl, 
20mM Tris pH 8] and twice with high salt buffer [1% v/v Triton X-100, 0.1% w/v SDS, 2mM 
EDTA, 500mM NaCl, 20mM Tris pH 8]. The beads were then incubated for 15 minutes at 
room temperature in 50μl Elution buffer [100mM NaHCO3, 1% w/v SDS]. The supernatant 
was kept and the elution repeated. The second supernatant was pooled with the first and 
cross-linking reversed by adding 20μl proteinase K (20 mg/ml) and incubation at 65⁰C 
overnight. DNA was extracted using a QIAquick PCR purification Kit (QIAGEN) and tested for 
specificity by PCR [95°C (15 minutes), then at 95°C (30 seconds), at 58 °C (30 seconds) and at 
72°C (30 seconds) for a total of 15 cycles]. DNA was sent to GATC Biotech (Konstanz, 
Germany) for library preparation and single-end sequencing. For analysis, SeqMonk software 
(Babraham Bioinformatics) was used. 
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Antibody Source Animal 
Msk1  Abcam ab81294 rabbit 
MLLN Millipore 05-764 mouse 
Histone H3  Abcam ab1791 rabbit 
Table 2.5: Antibodies used for XChIP 
 
2.4.5 Carrier Chromatin Immunoprecipitation (CChIP) 
Carrier ChIP is a technology used to characterise DNA binding in small cell numbers (O’Neill 
et al. 2006). For one IP 2x107 SL2 carrier cells were needed, as well as ~5x105 target cells. 
The cells were harvested and washed twice in cold NB buffer [15mM Tris pH 7.4, 5mM 
MgCl2, 15mM NaCl, 60mM KCl, 0.1mM EGTA, 0.5mM β-mercaptoethanol, 5mM Na-butyrate, 
0.1mM PMSF] and brought to a concentration of 2x107 cells per ml in NB buffer. An equal 
volume of 1% Tween20 in NB buffer was added and 1/200th of 100mM PMSF. The cells were 
stirred on ice for 15 minutes and then homogenised in a glass homogeniser (tight fit) with 1 
stroke per ml of cell suspension, before centrifuging at 2000 rpm for 20 minutes at 4°C. The 
nuclear pellet was then resuspended in 5% sucrose in NB buffer in half of the previous 
volume and centrifuged at 3000rpm for 10 minutes at 4°C. The nuclei were then 
resuspended in the same volume of Digestion buffer [0.32M sucrose, 50mM Tris pH 7.4, 
4mM MgCl2, 1mM CaCl2, 5mM Na-butyrate, 0.1mM PMSF] and the chromatin content 
measured using an Implen Nanophotometer. The nuclei were centrifuged at 2000rpm for 10 
minutes at 4°C and then brought to a final concentration of 0.5mg/ml with Digestion buffer, 
to which micrococcal nuclease (final concentration 50U/ml) was added. This was incubated 
at 37°C for five minutes, before 10μl 0.5M EDTA was added to terminate the digestion and 
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the chromatin placed on ice. It was subsequently centrifuged at 2000rpm for 5 minutes at 
4°C and the supernatant retained (S1) and stored at 4°C.  The pellet was resuspended in 1ml 
of Lysis buffer [1mM Tris pH 7.4, 0.2mM EDTA, 5mM Na-butyrate, 0.2mM PMSF] and 
dialysed (10kDa cut-off dialysis tubing, Sigma) overnight against 2 L Lysis buffer at 4°C 
overnight. The next day the chromatin was centrifuged at 1000g for 10 minutes at 4°C, the 
supernatant (S2) and pellet (resuspended in 200μl Lysis buffer, P) were retained. Chromatin 
integrity was checked on a 1% agarose-gel. Generally S1 and S2 were used and pooled, 10x 
Incubation buffer [50mM NaCl, 20mM Tris pH 7.4, 20mM Na-butyrate, 5mM EDTA, 0.1mM 
PMSF]  was added and made up to 1ml with distilled water. This was subsequently pre-
cleared with 100μl Protein A Sepharose (GE Healthcare) for 1 hour at 4°C. The chromatin 
was centrifuged for 10 minutes at 13000 rpm at 4°C and the pre-cleared supernatant taken 
and the antibody of interest added before incubation overnight at 4°C with slow rotation.  
The volumes of antibodies used were: 
H3K4me3 (R612, in house)   50μl per 100μg of chromatin 
H3K9acS10p (ab12181, Abcam) 10μl per 100μg of chromatin 
H3K27me3 (07-449, Millipore)           10μl per 100μg of chromatin 
The next day 100μl of pre-swollen protein A sepharose beads were added and incubated for 
3 hours at room temperature with rotation. The beads were then centrifuged (13000rpm, 10 
min, 4°C) and the supernatant removed and retained (labelled ‘UNBOUND’). The beads were 
then washed with Buffer A [50mM Tris pH7.4, 10mM EDTA, 5mM Na-butyrate, 50mM NaCl, 
0.1mM PMSF], Buffer B [50mM Tris pH7.4, 10mM EDTA, 5mM Na-butyrate, 100mM NaCl, 
0.1mM PMSF] and Buffer C [50mM Tris pH7.4, 10mM EDTA, 5mM Na-butyrate, 150mM 
NaCl, 0.1mM PMSF], centrifuging the beads for 5 minutes at 2000rpm at 4°C. The pellet was 
51 
 
then resuspended in 1% w/v SDS in Incubation buffer and incubated at room temperature 
for 15 minutes with rotation, centrifuged (13000rpm, 5 minutes) and the supernatant kept 
(labelled ‘BOUND1’). The elution was repeated and the supernatant kept (labelled 
‘BOUND2’). Samples BOUND1 and BOUND2 were pooled and the DNA extracted using a 
QIAquick PCR purification Kit (QIAGEN).   
 
2.4.6 FLAG purification  
We use HEK293 cells to overexpress FLAG tagged MLL1 protein and subsequently purify the 
MLL1 complex. HEK293 cells were transfected with an expression vector coding for FLAG-
tagged MLL protein (Figure 2.1 B: pMSCVneo, R. Slany, University Erlangen). After 3 days of 
transfection the cells were harvested and washed twice with TBS [50mM Tris, 150mM NaCl, 
pH 7.4].  The cells were then resuspended in Lysis buffer [1xTBS, 1 mM EDTA, 1% v/v Triton 
X-100], for one 10cm dish 500μl Lysis buffer was used. Cells were stirred on ice for 30 
minutes before they were centrifuged for 15 minutes at 13000 rpm and 4°C. 50μl of anti-
FLAG M2 magnetic beads (Sigma) were added and incubated for 2 hours at room 
temperature with rotation. The beads were then washed with TBS. Washing was monitored 
by measuring the absorbance of the supernatant at 280nm and continued until the 
absorbance of the wash solution was OD280 < 0.05. FLAG-MLL protein was then eluted from 
the beads using 5μg of 3x FLAG peptide (Sigma), diluted in 1ml TBS.  500μl of Elution 
Solution was added to the beads and incubated at 4°C for 30 minutes with rotation. The 
supernatant was collected and another 500μl of Elution Solution added and incubated at 4°C 
for 30 minutes with rotation. The supernatants were pooled and the protein concentrated 
using a Centrifugal Filter Unit (Millipore, Cut-off 30kDa), at 6000rpm for 10 minutes at 4°C. 
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2.4.7 Size exclusion chromatography 
Protein purification by size exclusion chromatography was performed using the Pharmacia 
FPLC system with a BioRad BioSil250 SEC column (7.8x300mm). Prior to loading protein 
samples, the column was equilibrated with TBS  buffer [50mM Tris, 150mM NaCl, pH 7.4], 
and then ~200μg of protein in 50μl TBS loaded. During the gel filtration run defined fractions 
were collected and elution profiles were generated by measuring the OD280 of the flow-
through. The elution profile allowed the identification of peak fractions, which were pooled 
and analysed by SDS-PAGE. 
 
2.4.8 Elutriation of LCLs 
Elutriation is a centrifugal separation technique, which separates cell according to size. This 
allows the separation of cells into different stages of the cell cycle (Kauffman et al. 1990). For 
elutriation the JE-5.0 Elutriation System (Beckman Coulter) was used with an Avanti J-26S XP 
Centrifuge (Beckman Coulter). Elutriation was performed at room-temperature and all used 
buffers were freshly prepared and used at room-temperature. Prior to use the chamber was 
assembled, fitted into the centrifuge rotor, connected to the pump and washed with 70% 
ethanol. The system was sub-sequently washed with 0.75xPBS and finally with EB buffer 
[0.75xPBS, 1% w/v BSA, 5mM EDTA] and any remaining air-bubbles removed. Whilst 
equilibrating the system the LCLs were prepared. The cells were colcemid treated for three 
hours before the elutriation run to arrest cells in the cell cycle. Colcemid (Biochrom), a 
microtubule-depolymerizing agent (Yang et al. 2010), was added to the medium to a final 
concentration of 0.1 μg/ml and incubated for 3 hours. ~400x106 cells were used per run, 
washed with EB buffer and finally resuspended in 10ml EB buffer, before passing them 
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through a cell filter (50μm cut-off) to remove any clumps. The centrifuge was set to 1800 
rpm and the pump to a flow rate of 110 for loading the cells into the system. Fractions of 
200ml were collected before increasing the flow rate. Fractions were collected at a flow rate 
of 11.0, 12.5, 14.5, 16.5 and 18.5 ml/min. The collected cells were centrifuged (1200 rpm, 5 
min at 4°C) and washed twice with cold 1xPBS. 1x106 cells were taken for flow cytometer 
analysis and the remaining cells were either used immediately for further analysis or stored 
as a pellet at -20°C. 
 
2.4.9 Flow Cytometer Analysis (FACS) 
FACS analysis was used to define the ploidy and the cell cycle phase of elutriated cell 
populations. About 1x106 cells were collected by centrifugation (1200 rpm, 5 minutes) per 
analysis. The supernatant was discarded, the cell pellet resuspended in 1ml of 80% 
ethanol/PBS and stored overnight at -20°C. After incubation the cells were centrifuged 
(800rpm, 10 minutes) and washed with cold PBS. The cells were centrifuged again at 800rpm 
for 10 minutes and the pellet resuspended in 500μl PBS with propidium iodide (PI, final 
concentration 0.1 mg/ml). The samples were incubated for 30-60 minutes at room 
temperature and then measured (Cyan ADP, Beckman Coulter). PI is excited at a wavelength 
of 488nm and emits light at 590nm, therefore the PE channel was used to measure PI 
incorporation into the DNA. 
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2.4.10 Immuno-fluorescence Microscopy 
To characterise protein distribution on chromatin, microscopy of immuno-fluorescence 
labelled G1 or G2/M cells was used. For microscopy, the cells were washed twice with PBS 
and counted. The cells were diluted to a concentration of 1x105cells/ml in KCM [120mM KCl, 
20mM NaCl, 10mM Tris/HCl pH 8, 0.5mM EDTA, 0.1% Triton X-100]. Ethanol-washed slides 
were fixed into chambers for the Cytospin (Thermo Scientific, Shandon Cytospin 4). 200μl of 
cells were put in the loading funnels and spun for 10 minutes at 1000rpm at room 
temperature. The slides with the cells were incubated in a bath of KCM for 10 minutes, 
before incubating with the primary antibody. Antibodies were diluted to the recommended 
concentration with KCM+0.1% w/v BSA. The slides were stored in a humidified chamber at 
4°C for one hour. After incubation the slides were washed twice in a bath of KCM for 10 
minutes, before adding the secondary antibody, which was labelled with a fluorochrome. 
The slides were incubated at 4°C for an hour again, prior to being washed twice with KCM 
for 10 minutes, and fixed by incubation in a bath of 4% formaldehyde/KCM for 10 minutes. 
Afterwards the slides were washed with dH2O, mounted with 10μl DAPI in Vectorshield 
solution (1μg/ml, Vector Laboratories) and then sealed with coverslips. 
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Antibody Source Dilution/Animal 
Msk1  Abcam ab32190 1:1000  / rabbit 
MLLN Millipore 05-764 1:1000 / mouse 
Histone H3K4me3 In house R612 1:500 / rabbit 
Histone H3K9ac In house R607 1:500 / rabbit 
Histone H3S10p Abcam ab32107 1:1000 / rabbit 
FITC 2nd, α-rabbit IgG Abcam ab6717 1:1000 / goat 
TRITC 2nd, α-mouse IgG Dako R0270 1:1000/ goat 
Table 2.4: Antibodies used for Immunofluorescence microscopy 
 
2.4.11 Co-immunoprecipitation 
Co-immunoprecipitation was used to verify the interaction of MLL1 complex subunits. It was 
performed in LCLs, HEKs and MEFs. For one IP 1x10
8
 cells were collected and washed twice 
in ice-cold PBS. The final cell pellet was resuspended in 500μl NP40 buffer [1% v/v NP-40, 
10% v/vv glycerol, 50mM Tris pH 7.5, 0.1% w/v sodium azide, 150mM NaCl]. The mixture 
was vortexed and incubated on ice for 20 minutes for cell lysis. Cells were then sonicated 
(high power, 10 seconds, Bioruptor Diagenode), the resultant lysates centrifuged for 20 
minutes at 13000 rpm, and the supernatant kept. Cell lysates were pre-cleared by adding 
Protein A or G sepharose beads, which were soaked overnight in NP40 buffer. The mixture 
was incubated on a rotating wheel for 30 minutes at 4°C before centrifuging at 13000 rpm 
for one minute.  The cleared supernatant was incubated overnight with 15μl of antibody at 
4°C on a rotating wheel.  Then 40μl of sepharose beads were added and incubated for 3 
hours on a rotating wheel at room-temperature. After centrifugation (3000 rpm, 1 minute), 
the supernatant was kept and the beads washed three times with high salt NP40 buffer [1% 
v/v NP-40, 10% v/v  glycerol, 50mM Tris pH 7.5, 0.1% w/v sodium azide, 200mM NaCl]. The 
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beads and the supernatant samples were mixed with SDS-loading buffer [20% w/v SDS, 
500mM Tris, pH 7.6, 50% glycerol, 1M DTT, Bromophenol blue] and analysed by SDS gel and 
Western analysis. 
Antibody Source Animal/Sepharose 
Msk1  Abcam ab81294 rabbit/sepharose A 
MLLN Millipore 05-764 mouse/sepharose G 
MLLC Millipore 05-765 mouse/sepharose G 
NFκB Abcam ab7970 rabbit/sepharose A 
Table 2.5: Antibodies used for Co-IP 
 
2.4.12 Gene Expression Arrays 
 Expression analysis was performed on MEFs using the NimbleGen system according to the 
manufacturer’s “NimbleGen Arrays User’s Guide”.  The array-slide contained 12 individual 
arrayS with 42,576 genes in triplicate on each. Therefore four control samples, four MLL1 
knock-down and four Msk1 knock-down samples were loaded. Firstly, 10μg of RNA per array 
were isolated (RNeasy, Qiagen) and reverse transcribed into cDNA using the cDNA synthesis 
System (NimbleGen). cDNA samples were subsequently labelled with the NimbleGen One-
Color DNA labelling kit. Then the samples were hybridized on the array 
(100718_MM9_EXP_HX12) and washed (NimbleGen Hybridization, Sample Tracking Control 
Kit & NimbleGen Wash Buffer). Finally the array was scanned with the MS 200 Microarray 
Scanner (NimbleGen). Data were processed with R (background correction and 
normalisation), and analysed with MeV (clustering, statistical analysis and visualisation).  
They are freely available, specialized tools to analyse microarray data, which incorporate a 
number of different algorithms. 
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3 Results 
3.1 Characterizing the interaction of MLL1 and Msk1 
MLL1 is a histone methyltransferase, which deposits methyl marks (me1-me3) on lysine 4 of 
histone H3 (H3K4me3). The methylation of histone 3 is involved in gene activation and is 
functionally linked with the acetylation of histone 3 and 4. We have previously shown that 
the processivity of the HMTase activity of the MLL SET domain is stimulated in vitro by 
acetylation together with phosphorylation at H3S10 (Nightingale et al. 2007). H3 acetylation 
is an abundant mark, whereas H3 phosphorylation only appears on a sub-fraction of 
nucleosomes in interphase cells and is deposited by ERK and p38 MAP kinases, which act 
through their downstream kinases Msk1 and 2 (Dyson et al. 2005; Soloaga et al. 2003).  We 
therefore hypothesized that Msk1 deposits the phosphorylation mark at H3S10 to stimulate 
MLL1 activity at specific loci. Here I wanted to explore if MLL1 and Msk1 interact in vivo and 
the nature of the interaction.  
 
3.1.1 Co-Immunoprecipitation experiments with MLL1 and Msk1 
If we assume Msk1 and MLL1 do functionally interact, two scenarios are possible. Firstly, 
MLL1 and Msk1 may act on the same sites on chromatin, but bind independently and do not 
directly interact (Figure 3.1 A, left). Alternatively, Msk1 may be a member (permanent or 
transient) of the MLL1 complex, similar to the histone acetyltransferases MOF or CBP (Figure 
3.1 A, right). We therefore performed co-immunoprecipitation experiments to see if in a 
MLL1 pull-down, Msk1 can be detected and vice versa. Msk1 is constantly expressed in cells, 
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but in an inactive, un-phosphorylated state, and only after phosphorylation is it functionally 
active (Duda  2012).  As Msk1 phosphorylation directly affects the activation status of Msk1, 
we used two different Msk1 antibodies (Figure 3.1 B): (1) A Msk1 antibody (Msk1-p), which 
was directed against the phosphorylated serine 376 residue (for LCLs and HEKs) or serine 
360 (for MEFs) and would bind active Msk1, due to species reactivity. (2) An antibody (Msk1) 
raised against the non-phosphorylated region between residues 752 and 802. This region is 
phosphorylated during the last stages of Msk1 activation and therefore the un-
phosphorylated region represents inactive Msk1 (Arthur 2008). All antibodies used for the 
co-immunoprecipitation experiments [un-phosphorylated Msk1 (Msk1), phosphorylated 
Msk1 (Msk1-p) and MLL1 (N- or C-terminus)] were tested for specificity by Western analysis, 
which also confirmed MLL1 and Msk1 expression in LCLs (Figure 3.1 C). To test the Msk1 
antibodies the same cell lysate was loaded on two adjacent lanes, which were separated 
(dashed line) and one lane was probed with the anti-Msk1 antibody and the other with the 
anti-Msk1-p antibody. The two membrane pieces then were re-joined and scanned together 
in order to highlight binding differences. The Msk1 antibody only detected one band (~90 
kDa), indicating it was specific for non-phosphorylated Msk1.  The Msk1-p antibody 
recognizes both the un-phosphorylated Msk1 (weak band on top), but mainly a double band, 
which is shifted downwards. This is consistent with Msk1 having multiple phosphorylation 
sites, which impacts on the electrophoretic mobility of the protein. These findings indicated 
that both Msk1 antibodies were specific for their targets (Figure 3.1 C, left). In contrast, the 
MLL1 antibodies specificity for the individual MLL termini were low (MLLN is ~320kDa and 
MLLC is ~180 kDa) and only the intact complex (full length MLL is ~430 kDa) was recognized 
reliably with both antibodies (Figure 3.1 C, right). 
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Figure 3.1:  Representation of the Co-IP experiments. (A) MLL1 and Msk1 have two options to interact with 
each other:  they might act independently at the same site on chromatin (left) or they might form a complex 
(right). The Co-IP experiments should address which interaction is more likely. (B) The domain structure of 
Msk1 is shown, as well as known phosphorylation sites. The epitopes for the antibodies against Msk1 used 
for the Co-IP are indicated. (C) Anti-Msk1 (left panel) and the anti-MLL1 antibodies (right panel) used for  the 
experiments were tested by western blotting on whole cell extract for specificity and expression  of MLL1 
and Msk1 in LCLs. Note the altered mobility of phosphorylated Msk1 (*). 
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First the interaction between the phosphorylated Msk1 and MLL1 was examined (Figure 3.2 
A, left). A cell lysate was prepared and a pull-down with the MLLN, the MLLC and NFκB 
antibodies was performed. NFκB was used as a positive control as it is known that it binds 
strongly to Msk1 (Vermeulen et al. 2003). In the pull-down with the MLL antibodies a strong 
clear band of the right size (~90 kDa) could be detected, as well as in the control pull-down 
with NFκB. In the control pull-down a prominent band of smaller size (~55kDa, asterisk), 
which appears as a smear, could also be detected. Furthermore, in the input samples small 
bands of ~25 kDa were found (marked with an asterisk). Later experiments showed that 
these were the heavy or light chain of the used antibodies (data not shown). As the MLL
N
 
and the MLLC antibodies showed no differences, for further experiments only the MLLN 
antibody was used.  
To validate the binding, the co-IP was reversed (Figure 3.2 A, right). A pull-down with Msk1-p 
was performed and the western probed for MLL1N. The western showed a clear MLL1 band. 
This finding supports the hypothesis that MLL1 and Msk1 interact.  
However, this experimental set up, did not rule out that the interaction between MLL1 and 
Msk1 was bridged by chromatin. In order to release the proteins from the DNA a high 
concentration of ethidium bromide (50μg/ml) was added (Lai & Herr, 1992; Schröter  et al., 
1985). Under these conditions (Figure 3.2 B), phosphorylated Msk1 was still detected in the 
MLL pull-down (A) and MLL1 could be still observed in the Msk-p pull-down (B).  
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Figure 3.2: Co-Immunopreciptiation experiments for MLL1 and Msk1. (A) Co-IP experiments were 
established in LCLs. Left: A cell extract was prepared and MLL
N
, MLL
C 
and NFκB were pulled down with 
antibodies. The beads and their corresponding Input samples were loaded on a 12% gel.  It is known that 
Msk1 and NFκB bind, so this IP was used as a positive control. Right: A Co-IP for Msk-p was performed and 
the beads and the supernatant sample were loaded on a 4% gel. (B) Co-IP including ethidium bromide. 
During the preparation of the cell extract 50 μg/ml ethidium bromide was added to release chromatin 
proteins from the DNA. Asterisks  indicate the IgG heavy (55 kDa) or light (25 kDa) chain of the antibodies. 
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In the next experiment, the interaction between the non-phosphorylated Msk1 (inactive) 
and MLL1 was examined and therefore the immuoprecipitation repeated with the antibody 
that recognized non-phosphorylated Msk1 (Figure 3.1 B). In the pull-down with MLLN a 
strong band for Msk1 was detected (Figure 3.3 A, left), which also showed up in the positive 
NFκB pull-down. In the reverse experiment however, only a very weak Msk1 pull-down could 
be detected (Figure 3.3 A, right).  The experiment was repeated with ethidium bromide 
added to the lysates (Figure 3.3 B).  This confirmed that Msk1 could be detected in the MLL1 
pull-down, but no MLL1 could be detected in the pull-down with non-phosphorylated Msk1. 
The interpretation of these findings are not clear, as it could suggest that MLL1 interacts 
with Msk1 in its active, phosphorylated form, but as not in the inactive non-phosphorylated 
form. However it is also possible that the antibody disrupts the MLL1-Msk1 interaction.  
In order to validate and expand these Co-IP results, IPs with MLL
N
 and Msk1-p were repeated 
in different human and murine cell lines, with ethidium bromide (50μg/ml) added to the cell 
lysates. As shown in Figure 3.3 C and D, experiments using human HEKs and mouse 
embryonic fibroblasts confirmed the binding of MLL1 and Msk1-p.  
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Figure 3.3:  Co-immunoprecipitation for MLL1 and Msk1. (A) The Co-IP experiment was repeated using an 
antibody that recognizes un-phosphorylated Msk1. In the MLL1 pull-down Msk1 could be detected, but only 
a weak MLL1 band in the Msk1 pull down. (B) The experiment was repeated with 50μg/ml ethidium bromide 
in the cell extract. Msk1 could be detected in the MLL1 pull -down, but in the Msk1 pull-down no MLL1 could 
be detected. (C) The Co-IP experiments were repeated in MEFS and HEKs. Ethidium bromide was added to 
all cells extracts. In all tested cell lines Msk1-p could be detected in the MLL1 pull-down. (D) In the reverse 
experiments MLL1 could be detected in the Msk1-p pull-downs. 
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3.1.2 FLAG-tagged MLL1 complex 
In a second approach to characterize the putative MLL1 and Msk1 interaction, we over-
expressed FLAG-tagged MLL1 (pMSCVneo vector was a gift of Slany, University of Erlangen) 
in HEK cells and purified the associated protein complex. HEK cells were transfected with the 
FLAG-MLL1 encoding vector or with a GFP containing vector to control transfection 
efficiency (Figure 3.4 A) and transfected cells were shown to express FLAG MLL1 by western 
analysis (Figure 3.4 B).  
In the next step the transfected cells were harvested, lysed and the MLL1-Flag protein 
purified using α-FLAG IgG coated beads.  A concentrated sample was run on a size exclusion 
gel filtration column to analyse the purity of the immuno-precipitated complex protein 
(Figure 3.4 C). As a control a background sample was run (supernatant of the concentration 
process). A single peak was detected in the elution profile of the FLAG purified protein 
sample (fractions 15-16, 3.75-4.5ml, marked with an asterisk), which couldn’t be detected in 
the background profile. However, in the fractions 26-36 (6.5-9 ml) multiple peaks could be 
detected in both elution profiles, which are likely to reflect non-specific binding of proteins 
to the beads (MW ~30 kDa). 
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Figure 3.4:  Overexpression of FLAG-MLL1 in HEK293s. (A) HEK cells were serum starved overnight, before 
incubation for 7 hours with transfection medium. After 3 days the cells were collected. Cells transfected 
with a GFP expressing vector were controlled for transfection efficiency with fluorescence-microscopy. (B)  
The transfected cells were checked for FLAG expression. A single band was detected, which was absent in 
non-transfected cells (Control). Actin was used as a loading control. (C) A concentrated sample and 
background sample (supernatant of the concentrated protein) was run on a size-exclusion gel-filtration 
column to control the quality of the purified protein. A  unique peak in the FLAG-protein elution profile 
(fraction 15-18, asterisk), is likely to be a large molecular weight complex. In fraction 26-36 multiple peaks 
can be found in both elution profiles, which are likely to be non-specific protein binding to the beads 
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The purified protein complex was loaded on a gel and stained to visualize protein bands 
(Figure 3.5 A).  A number of bands (~10x) could be detected, which we assumed were the 
MLL1 complex components. The protein was then analysed by western (Figure 3.5 B). The 
membrane was firstly probed with an antibody against the FLAG-tag and visualized a band at 
the top of the membrane, in both the Input and the purified protein sample (left panel). 
Secondly an antibody against Msk1 (phosphorylated) was used and visualized a band in the 
upper third of the membrane, in both (Input and purified protein) sample (middle panel). 
Lastly the membrane was probed with an NFκB antibody, as this is a known interaction 
partner of Msk1. This detected a band in the Input sample but not in the purified protein 
complex. The smear between the Msk1 band and the NFκB band (marked with *) was cross-
reaction of the NFκB antibody (right panel). 
Taken together these results strongly support, that MLL1 does interact with Msk1 directly. 
The interaction is unlikely to be bridged by chromatin and may be limited to the active, 
phosphorylated form of Msk1. This suggested that active Msk1 is probably a member of the 
MLL1 complex. However, it is not yet clear if the MLL1-Msk1 interaction is a transient 
interaction or whether Msk1 is a permanent member of the MLL1 complex.  
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Figure 3.5: MLL1-FLAG complex. (A) The MLL-complex was isolated by FLAG-bead purification. On a SDS gel 
stained with silver-nitrate, a number of bands can be detected (indicated at the side with bars) (B) Western 
blotting, FLAG-tagged MLL (left), an Msk1 can be detected in the FLAG-bead pull-down (middle). In contrast, 
NFκB (a known interaction partner of Msk1) cannot be detected in the purified complex. 
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3.2 MLL1 and Msk1 binding in vivo 
In the previous experiments, we used immunoprecipitation and purification of FLAG-tagged 
MLL1 complex to investigate MLL1 and Msk1 interaction. These co-immunoprecipitation 
experiments suggested that MLL1 interacts strongly with Msk1. Moreover, analysis of a 
FLAG–purified MLL1 complex showed that Msk1-p can be found in the purified MLL1 
complex. Following these experiments we wanted to examine the distribution of MLL1 and 
Msk1 binding in vivo and therefore used a Chromatin-immunoprecipitation followed by 
sequencing (ChIP-Seq) approach in mouse embryonic fibroblasts (MEFs).  
 
3.2.1 Establishing an XChIP protocol for MEFs 
We chose MEFs because these are primary non-transformed cells with a normal karyotype, 
and are therefore a good model to study MLL1 and Msk1 binding under normal physiological 
conditions. Chromatin-immunoprecipitation for DNA-bound transcription factors requires 
cross-linking to the DNA. The cells were therefore treated with formaldehyde and the 
extracted chromatin was fragmented with sonication. This step was crucial, as sequencing 
requires chromatin fragments of ~250 bp. Sonication optimization (7 cycles, high intensity) 
resulted in a narrow spread of DNA fragments ranging from 100-500bp, with the majority in 
the 200-300bp range (Figure 3.6 A). Every batch of chromatin was validated in this way 
before use, as appropriate chromatin fragment sizes are essential for immunoprecipitation 
and subsequent library preparation.  
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For the immunoprecipitation the same antibodies were used as for the co-IPs (Chapter 3.1), 
one directed against the N-terminal domain of MLL1 and one directed against the 
phosphorylated serine 360 of Msk1 (activated Msk1, Figure 1.9 A). Additionally an antibody 
against the histone H3 C-terminal tail was used as a positive control. This domain is not 
known to contain modifications, so binding is assumed to be unaltered by histone 
modification.  To control for non-specific binding, a ‘mock’ immunoprecipitation was 
performed, in which no antibodies were used. The precipitated chromatin was analysed in a 
short PCR (15 cycles) for amplification of two genes: HoxA4, a known MLL1 target gene and 
GAPDH as a reference gene (Figure 3.6 B). The pull-down with the H3-tail antibody (positive 
control, lane 1) showed amplification for both genes, indicating that the precipitation was 
efficient. Furthermore, the no-antibody pull-down (negative control, lane 4) showed no 
amplification of the two genes, indicating that non-specific binding was minimal. In contrast, 
chromatin pulled down with the MLL1 antibody amplified HoxA4, but not GAPDH. Likewise 
chromatin pulled down with the Msk1 antibody, showed strong amplification of HoxA4, but 
only a weak one for GAPDH. This suggested both precipitations were successful and pulled 
down known target genes. Immunoprecipitated DNA was subsequently sent to GATC Biotech 
for library preparation and 50bp single-end sequencing on the Illumina HiSeq2000. A 
coverage of 113,852,000 sequenced reads in the Msk1 library and 82,796,700 sequenced 
reads in the MLL1 library was achieved.  
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Figure 3.6: Chromatin preparation for Next Generation Sequencing. (A) Chromatin was fixed with 
formaldehyde and then sonicated. For sequencing small chromatin fragments ~250 bp were needed. 7 cycles 
(30 sec on/off) at high intensity resulted in chromatin between 100 and 500 bp, but with the majority of 
fragments between 200-300 bp. (B) In order to control the quality of the pull down, a positive  control 
(antibody that recognizes the histone H3 C-terminal tail) and a negative control (no antibody control)  were 
performed. A PCR was performed on the precipitated DNA to validate the antibody binding efficiency. HoxA4 
was chosen, as it is a known MLL1 target gene. No binding was observed in the negative control (lane4), 
binding of Msk1 and MLL1 at HoxA4 was observed (lane2 & 3 upper panel), whilst no or little binding was 
detected in the GAPDH reference gene (lane2 & 3, lower panel. The primers were placed over the TSS of the 
two genes. 
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3.2.2 Analysis of the sequencing results of MLL1 and Msk1 
For the analysis the Galaxy/Cistrom server  was used (https://usegalaxy.org). In Figure 3.7 A, 
a screen-shot of the raw data is shown (wiggle plot). The ChIP-Seq data of MLL1, Msk1 and 
H3K4me3 for primary MEFs (Karolchik et al., 2014; Rosenbloom et al., 2013; Data generated 
by B. Ren, Ludwig Institute for Cancer Research) are shown over the Mus musculus HoxA 
cluster [Chromosome 6, 52,100,000 – 52,200,000], including known RNA products from 
these loci and major transcription start sites (TSS). The peak profile of H3K4me3 shows high 
enrichment and well defined peaks. The profiles of MLL1 and Msk1 show less enrichment 
and a more ‘spiky’ appearance, but appear to bind preferably to TSS where H3K4me3 can be 
detected. The first step was to identify regions, which were significantly enriched for reads. 
Therefore a peak detection algorithm (‘peak caller’) was run. In Galaxy it is based on the 
MACS peak caller for peak detection.   
In order to compare regions bound by MLL1 or Msk1 and the H3K4me3 distribution, a Venn 
diagram was created (Galaxy tool, Figure 3.7 B). All binding sites of MLL1, Msk1 and 
H3K4me3 identified with the ‘peak caller’ were compared (Figure 3.7 B). The analysis 
showed overlap between  MLL1 and Msk1 binding sites (2090 binding sites), however, the 
majority of sites were occupied by either MLL1 only (2060 sites) or Msk1 only (3646 sites). 
These data, showing a 30-40% overlap, between the sites, represent compelling data that 
the two proteins can act in tandem to regulate genes. The data also showed that the general 
MLL1/Msk1 binding  does not correlate with H3K4me3 , which was more abundant. 
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Figure 3.7: Sequencing Analysis – peak identification. (A) Screen Shot raw peak data over the HoxA cluster 
is shown. In order to identify high confidence binding of MLL1, Msk1 and H3K4me3 (Rosenbloom et al. 2013; 
Karolchik et al. 2014) to the genome, the MACS14 ‘peak caller’ algorithm was run. (B) Venn-diagram, 
comparing the binding sites of MLL1, Msk1 and H3K4me3, identified by the ‘peak caller’. MLL1 and Msk1 
show an overlap of a subgroup of peaks (~20%). However, the majority of MLL1 and Msk1 do not correlate 
nor does it correlate with H3K4me3. 
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In the next step  a probe trend plot was created (Figure 3.8).  Probe trend plots show an 
average pattern or distribution of reads across known TSS sites (Glaxy/Cistrone CEAS tool). 
Here the average read pattern over each TSS (-5000 and +5000bp to each side) bound by 
MLL1 and Msk1 were analysed (Figure 3.8 A).  The trend plot showed that MLL1 and Msk1 
bind preferentially on the TSS, but that they also can be found over the adjacent 1000bp, 
with a broad peak of binding from ~-500 to +1000. The two profiles are extremely similar 
and show profiles typical for TSS binding factors.  In comparison the trend plot for H3K4me3 
is shown (Figure 3.8 B), with a typical methylation peak over the TSS (compare Figure 1.3). 
However, while MLL1/Msk1 seem to bind directly over the TSS (indicated by black line), this 
position seems to be non-methylated, probably due to nucleosome redistribution by bound 
transcription factors at the TSS. H3K4me3 is mainly found ~-500bp  (small peak) and 
~+500bp from the TSS (large peak). 
In the next step of the analysis the two peak data set (MLL1 binding vs. Msk1 binding) were 
compared, with the focus on the peaks that were bound by both MLL1 and Msk1. In Figure 
3.9 the scatter plot is shown. The R-value of the correlation is 0.91, indicating that the 
binding patterns of MLL1 and Msk1 on the shared peaks were simillarly strong.  
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Figure 3.8: Sequencing Analysis – TSS probe analysis. (A) The probe trend plot shows the average 
distribution of reads across TSS loci. It covers the region -5000 bp and +5000 bp around the TSS and shows an 
enrichment of MLL1 and Msk1 binding over the TSS. The black line represents the TSS. (B) Here the same 
analysis was done for H3K4me3. H3K4me3 is enriched ~-500 and +500 bp from the TSS, but not on the TSS 
itself. Data from Encode, generated by B. Ren, Ludwig Institute for Cancer Research (Rosenbloom et al. 2013; 
Karolchik et al. 2014) 
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Figure 3.9: An analysis of MLL1 and Msk1 binding correlations. Significant binding of MLL1 and Msk1 were 
identified with the ‘MACS peak caller’. It showed that MLL1 and Msk1 binding strength on the shared peaks 
correlates highly.  
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In this analysis MLL1 and Msk1 were cross-linked to the DNA in order to study their 
distribution of binding under physiological conditions and to identify MLL1 and Msk1 target 
genes. We have shown that MLL1 and Msk1 binding strongly correlate, but this also  
matches with the distribution of H3K4 tri-methylation in chromatin. These findings support 
our previous results that indicated there is a physical interaction between MLL1 and Msk1. 
The sequencing results confirmed the Hox genes are MLL1 target genes, although not the 
entire cluster was bound, consistent with the previous  analysis of MLL1 target genes.   
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3.3 Characterising the functional impact of MLL1 and Msk1 
regulation 
In the last section we established that MLL1 and Msk1 physically interact and bind to the 
same sites in the genome. In this section we examine if these proteins have a common 
regulatory effect at MLL1 target genes, using a MLL1 and Msk1 knock-down approach. 
In Figure 3.10 an overview of the experiments is shown. Firstly a transient shRNA-mediated 
knock-down of MLL1 and Msk1 needed to be established. We chose to use MEFs to allow 
comparison with the binding experiments that have been described. Transient knock-down 
was used rather than a stable knock-out, as we wanted to characterize the immediate 
changes in gene expression in response to MLL1 and Msk1 down-regulation as these are 
likely to reflect direct effects. In the next step we assessed if these knock-downs led to a 
change in the expression of known MLL1 target genes (i.e. HoxA locus; Hess 2004). Previous 
data have shown that MLL1 and Msk1 bind a large number of sites in the genome (Chapter 
3.2). Therefore changes in expression on a genome-wide scale were studied using a 
microarray approach. In the final experiment two representative MLL1 target genes, HoxA4 
and HoxA5 were examined in knock-down cells to characterize the changes of key MLL1-
associated histone modifications (H3K4me3, H3K27me3 and H3K9acS10p) in response to 
reduced levels of MLL1 and Msk1. 
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Figure 3.10: Experimental design/workflow. (1) A transient knock-down for MLL1 and Msk1 in MEFs 
needed to be established. (2) The functional impact was validated, as the HoxA cluster was screened for 
changes in expression in response to the knocked down proteins. (3) Microarray analysis was performed to 
examine the effect of MLL1 and Msk1 KD on gene expression on a global level. (4) Genes impacted by MLL1 
and Msk1 knock-down were correlated to MLL1/Msk1 genomic binding and two HoxA genes were screened 
for changes in key histone modifications. 
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3.3.1 Establishment of a transient knock-down of MLL1 and Msk1 in MEFs 
The focus of this part of the study was to evaluate the functional impact of MLL1 and Msk1 
on gene regulation in a physiological context. We decided to work with mouse embryonic 
fibroblasts (MEFs), as these primary cells have no genomic alterations (e.g. oncogenes or 
virus-infection) and as embryonic derived cells, they express HoxA genes, known MLL1 target 
genes (Hanson et al. 1999).  
Initial experiments established conditions to transfect these cells with MLL1 and Msk1 siRNA 
knock-down vectors (Origene, Msk1: TR504795, MLL1: TR517798) which deliver 4-5 shRNA 
vectors per kit and a GFP- containing vector, which was used as a control. Once the vector is 
in the target cell it expresses short hairpin RNA, which is processed into siRNA that interacts 
with the RISC complex. This subsequently results in the cleavage of the target mRNA, 
resulting in reduced transcript and protein abundance (Macrae et al. 2006). Initially a range 
of different transfection methods were tested using the GFP vector, including lipofectamine 
(Sigma), X-fect (Clontech) and electroporation (Gene pulser XCell, BioRad). Evaluation of 
transfection efficiency using GFP fluorescence showed that all methods showed good cell 
viability (80% - 95%), however the transfection efficiency was low in all methods (for  
electroporated MEFs: Figure 3.11). This Indicates a shift in the main peak of GFP positive 
cells, but only ~20%  of the cells were highly transfected, whereas with X-fect and 
lipofectamine only ~10% were GFP-positive (data not shown). Therefore electroporation was 
used in subsequent experiments.  
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Figure 3.11: Establishing MEF transfection protocols. (A) Cell viability was controlled with light microscopy 
and trypan blue staining. Separation of live cells (attached to the plastic) and dead cells (floating) was 
possible. Here electroporated cells are shown. With optimised conditions, cell survival of 80% was achieved 
(B) The transfection efficiency of GFP was controlled by FACS analysis with cell count on y-axis and GFP 
fluorescence indicated on the x-axis. Lower panel indicates quantification of the cells in the R2 gate, which 
corresponds to cells. A shift in the measured peak could be detected, however the rate of highly transfected 
was around 22%. 
81 
 
We initially established the protocol for Msk1. In the next step the available shRNA vectors 
were tested for the best reduction of the target transcript. Out of the five available vectors 
only one showed a significant reduction of Msk1 RNA levels (data not shown) and was 
chosen for further experiments.  
As it was a transient knock-down only a short-lived reduction in RNA levels was                                                                                  
expected. We therefore examined the reduction of Msk1 RNA levels over an extended time 
scale and found that at ~12 hours post-transfection Msk1 RNA abundance was at the lowest 
and after ~24 hours this had recovered. However, even at the maximal knock-down, ~40% of 
Msk1 transcripts remained (Figure 3.12 A). 
We suspected that low transfection efficiency was the reason why the knock-down levels 
were so low, as the majority of the cells were only poorly transfected. As these shRNA mir 
vectors contained a puromycin resistance cassette (Figure 2.1.A), we used this antibiotic to 
select for the transfected cells. MEFs were transfected and rested for six hours to allow the 
cells to recover and reattach to the culture flasks. Then they were treated with puromycin, 
and 20 hours after transfection the cells were collected for analysis. As shown in Figure 3.12 
B, the living cells remained bound to the flask, whereas dead cells  became detached and 
could be removed. qPCR analysis of the puromycin-selected cells showed that after 24 hours 
Msk1 RNA was still reduced by ~50% while the untreated cells had fully recovered (Figure 
3.12 C). 
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Figure 3.12: Establishing Msk1 knock down protocol. (A) The knock-down was transient and therefore the 
time-point with the maximal effect needed to be identified. For a control, cells were mock-transfected with a 
GFP vector. Cells were collected at the indicated time-points post transfection (n=2). Msk1 RNA levels were 
lowest after ~12 hours (about 35%) but recovered completely after 24 hours.  (B) As transfection efficiency 
was low (~20%) transfected cells were treated with puromycin to the non-transfected cells. The surviving cells 
remain attached to the flask, whereas dead cells would float in the medium. Images were taken 24 hours after 
transfection. (C) Cells that were treated with puromycin showed significantly lower Msk1 transcript levels 
after 24 hours than those that were not treated, indicating that non-transfected cells are susceptible to 
puromycin-induced killing. 
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In order to see, if the changes Msk1 in transcript abundance would result in a change of 
protein level, western blots were performed. Previous studies suggest that protein levels 
reduce slower than RNA levels and that 20 hours post-transfection is likely to be the optimal 
time for reduced Msk1 protein knock-down, so the cells were harvested at this time point 
(both treated and untreated with puromycin) and analysed (Figure 3.13 A). The membrane 
was first probed with an antibody against Msk1 and then with an antibody against β-actin to 
control for loading. Cells, which were not selected with puromycin had only minimally lower 
Msk1 protein levels than the mock-transfected cells (Control). In contrast, puromycin-
selected cells had extremely efficient Msk1 knock-down (~99% KD).This suggest that poorly 
transfected cells, which would buffer the observed reduction of RNA or protein levels, die 
during antibiotic selection and only highly transfected cells survived. 
Next, the specificity of the Msk1 knock-down was confirmed. In order to exclude off-target 
effects, the impact of the knock-down on a similar gene/protein to Msk1 was examined. 
Msk2 is a mammalian homologue of Msk1, which shares ~76% sequence identity and was 
therefore chosen to verify the sequence specificity of the shRNA. In Figure 3.13 B Msk1 and 
Msk2 transcript abundance was analysed 20 hours after transfection. Msk1 RNA levels were, 
as seen before, reduced to ~40% whereas Msk2 transcript levels were comparable with 
mock transfected cells (Control). Subsequent western analysis confirmed that only Msk1 was 
affected, as Msk2 levels remained stable (Figure 3.13 C). 
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Figure 3.13: Establishing the Msk1 knock-down protocol. (A) Knock-down cells treated with puromycin 
showed a significant lower level of Msk1 protein after 20 hours. Msk1 abundance in GFP-control transfected 
cells (Control) and those in KD cells either untreated (Msk1) or treated with puromycin (Msk1 KD & Puro) 
are shown. Actin is used as a loading control. The extent of knock-down is shown below the blots. (B) 
Evaluating knock-down specificity. Cells were harvested after 20 hours correlating with the lowest protein 
levels. At this time point Msk1 transcript levels were still reduced by ~60% whereas Msk2 transcript levels 
were comparable to mock-transfected cells (control). Error bars indicate SD (n=3). (C) After 20 hours Msk1 
protein is efficiently knocked-down, whereas Msk2 protein levels were unaltered. 
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Having established the conditions for the Msk1 knock-down, these were applied to the MLL1 
knock-down.  For MLL1 knock-down, four vectors were provided (Origene), which were 
tested and the most efficient chosen for succeeding experiments. In the next step, MLL1 
transcript levels were monitored over time.  Similar to the Msk1 knock-down, MLL1 RNA 
levels were lowest ~12 hours after transfection (~20% of original level) and fully recovered 
after 24 hours when not treated with puromycin (Figure 3.14 A).  
Next the specificity of the MLL1 shRNA was controlled by analysing the transcript 
levels of the MLL1 homologues MLL2, MLL3 and MLL5 in MLL1 knock-down cells.  As shown 
in Figure 3.14 B, MLL1 levels were reduced about 60%, whereas the MLL1 homologues had 
comparable transcript levels to the mock-transfected cells (Control). Finally, the level of 
MLL1 protein in the knock-down cells was determined. We treated transfected cells with 
puromycin and harvested the cells 20 hours post transfection (Figure 3.14 C).  These were 
the same conditions as used for the Msk1 knock-down, however, the MLL1 protein levels 
were only reduced by ~60%. Analysis of transfected cells at later time-points (30 and 48 
hours after transfection), found MLL1 protein at ~40% of control cell levels (Figure 3.14 D).  
Furthermore, the selected cells did not cope with the reduced levels of MLL1 and no viable 
cells were found 72 hours after transfection, even when cells were incubated in medium 
without puromycin. For the following experiments MLL1 knock-down cells were treated with 
puromycin after 6 hours and harvested after 20 hours as for the Msk1 knock-down protocol.  
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Figure 3.14: Establishing MLL1 knock-down protocol. (A) As the knock-down was transient, cells were 
harvested at indicated time-points. MLL1 transcripts were maximally knocked down at ~12 hours post 
transfection and recovered by 24 hours. (B) In order to test the specificity of the MLL shRNA vector, the 
transcript levels of MLL2, MLL3 and MLL5 were analysed in MLL1 knock-down cells. At 20 hours after 
transfection and treatment with puromycin, MLL1 transcript levels were ~40% of control lev els, whereas 
MLL2, MLL3, MLL5 and control cell transcript levels were ~100%. Transcript abundance was compared with 
the MLL1 transcript levels in mock-transfected (Control) cells, which was normalized to 1.0 (C) Under the 
same conditions MLL1 protein was reduced by 63%. RNA Polymerase II (Pol II) was used as a loading 
control. (D) Cells harvested 30 or 48 hours post-transfection showed no further reduction in MLL1 protein 
levels.  
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3.3.2 Changes of MLL1 target genes in knock-down cells 
In the previous section conditions were established to create cells with significantly reduced 
levels of either MLL1 (~63% knock-down) or Msk1 (~99% knock-down). These cells were then 
studied for changes of expression at MLL1 target genes. We focussed on the HoxA genes and 
Meis1, as MLL1 is known to play an essential role in haematopoiesis through the 
maintenance of Hox gene expression (Argiropoulos & Humphries 2007b). Likewise, in MLL 
rearranged leukaemias, several HoxA genes and the oncogene Meis1 are consistently up-
regulated (Horton et al., 2005; Orlovsky et al., 2011).   
In order to capture changes in expression, RNA from knock-down and mock-transfected cells 
was isolated and analysed with qPCR. In Figure 3.15 A, a cartoon of the HoxA cluster is 
shown, which consists of 11 genes in mouse. In MLL1 knock-down cells, the expression of 
nearly all HoxA genes was down-regulated.  Hox genes at the edge of the cluster (HoxA 1, 2 
and HoxA 11, 13) showed only a moderate reduction of transcript levels (~30%).  Similarly 
HoxA 7 and 9 were down-regulated by ~40%, whereas the greatest impact was seen on the 
expression of HoxA 3, 4, 5, 6 and 10, which were reduced by ~70% (Figure 3.15 B). A 
strikingly similar response was observed in Msk1 knock-down cells (Figure 3.15 C). HoxA 1, 2 
and 11 showed no or moderate reduction in expression, HoxA 9 was down-regulated by 
~40%, whereas all the other HoxA gene transcripts were reduced by 50-60%. These findings 
suggest Msk1 contributes to the regulation of these known MLL1 target genes. However, 
Meis1 expression was not changed in MLL1 or in Msk1 knock-down cells. We next examined  
whether this was consistent across the genome. 
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Figure 3.15: Effect of MLL1 or Msk1 knock-down on HoxA and Meis1 gene expression. The Hox genes are 
well known MLL1 target genes. Therefore the effect of MLL1 and Msk1 knock-down on HoxA genes was 
examined. (A) Cartoon of the murine HoxA cluster. (B) The changes of expression in MLL1 knock-down cells 
at 20 hours post-transfection. (C) The changes of expression in Msk1 knock-down cells at 20 hours post 
transfection.  Transcript levels in mock-transfected cells (Control) are set at 1.0. Transcript abundance was 
normalized to β-actin and is presented +/- SD (n=3). Red asterisks indicate significantly down-regulated 
genes (paired t-test, p<0.05*, p<0.01**, p<0.001 ***). 
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3.3.3 Changes of gene expression on a genome wide level in knock-down cells 
Our findings that the HoxA genes were down-regulated in MLL1 or Msk1 knock-down cells in 
a comparable manner suggested that MLL1 and Msk1 are functionally connected, at least at 
the HoxA loci. Our genome-wide analysis (Chapter 3.2) showed that MLL1 and Msk1 bind to 
a number of same sites in the genome, suggesting these proteins regulated a larger number 
of genes beyond the HoxA locus.  Therefore changes in gene expression on a genome-wide 
scale were examined.  
For this analysis the 100718_MM9_EXP_HX12 microarry from NimbleGen was used. 
This slide contains 12 individual arrays, each representing 42,576 probes in triplicate. Four 
samples for each knock-down and mock-treated cells were prepared. RNA was extracted, 
reverse-transcribed into cDNA and labelled with Cy5. The labelled samples were hybridized 
onto the arrays and scanned.  In the first step of the analysis, the quality of the scan was 
validated (Figure 3.16 A). Ideally the same amount of cDNA should hybridize to each array 
and give comparable fluorescence signals. However signal intensity can vary due to slightly 
different loading, inefficient hybridization or differential scanning quality on different parts 
of the slide. Hence, for each array the range of signal readings was analysed. These are 
presented as box and whisker plots, where the median of the box-plots represents the 
average density of the scan and the intensity of 75% of the features on the array lie within 
the box. In this format, the maximum and the minimum intensities lie at the end of the 
whiskers. Two arrays showed a significant difference in signal intensity from the other 
samples, suggesting that there was a problem with either the labelling or hybridization (e.g. 
Control2 & Msk2, Figure 3.16 A). For further analysis these two samples were excluded 
(Graph 1 and 2). In order to make the arrays comparable a quantile normalisation was 
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performed using the RMA (Robust-Multi-Array Average) pre-processing methodology 
implemented in R (Krause & Olson 2000). This normalization process adjusts for systematic 
errors arising from differences in the method or dye intensity to make further analysis 
meaningful (Graph 3).  The normalised data were then analysed by principal component 
analysis (Figure 3.16 B), which is a mathematical algorithm that identifies patterns in the 
data sets, by identifying maximal trends, called principal components (Ringnér 2008). The 
analysis showed that the four samples for the MLL1 knock-down cells were closely clustered 
near the origin, indicating that they were quite similar (Figure 3.16 B). In contrast the three 
samples from Msk1 knock-down cells were mainly located to the lower left quadrant, 
whereas the three samples from control cells were located mainly in the upper left 
quadrant, and showed a wider variation between the data sets. However, this was 
acceptable, as each cell-condition formed a cluster with a defined territory.  
In order to identify differentially expressed genes between the control and the knock-down 
cells, SAM (significance analysis of microarrays) analysis was performed in MeV (Tusher et al. 
2001). The results of changes in expression were represented in a heat map (Figure 3.17 A). 
At the top of the heat map, a hierarchical tree diagram is shown, which visualizes the 
relationship between the data sets and shows that the three cell conditions are significantly 
different from each other. Each line represents a gene, which showed a change of 
fluorescence during scanning in the different cell types. These changes in fluorescence 
intensity correlate with changes in expression. In total 3912 genes were statistically different 
between the knock-down and the control cells (fold change cut-off: FC>2). The colouring 
scale is relative, in which higher gene expression is marked in red and lower gene expression 
in green. 
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Figure 3.16: Microarray analysis of MLL1 and Msk1 knock-down cells. (A) In the first step the microarry 
scans were quality controlled. Two extreme outliners were excluded from the analysis (Con2 & Msk2: 
compare panels 1 and 2) and all remaining samples were normalized (panel 3). (B) A Principal Component 
Analysis was performed to evaluate the differences between the three groups: Control (1, 3 & 4), MLL KD 
(1, 2, 3 & 4) and Msk KD (1, 3 & 4). 
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Figure 3.17: Significance analysis of gene expression changes for MLL1 and Msk1 KD. (A) To analyse a SAM 
(Significance analysis of microarrays) was performed to find significant changes between patterns of gene 
expression in Control, MLL1 knock-down and Msk1 knock-down cells. Gene expression changes are indicated 
by colour intensity of a range from 2.7 down (green) to 2.7 up (red). Samples are clustered by hierarchical 
tree at the top of the plot. (B) In total 3912 genes changed and could be clustered into five groups. The 
number of genes in each cluster is indicated on the right, the hierarchical tree on the left. (C)  Out of these 
3912 genes only 19% were down-regulated in both MLL1 and Msk1 knock-down cells (Cluster 3) and only 
11% were up-regulated in both knock-downs (Cluster 5). This indicates the majority of genes respond 
differently to MLL1 or Msk1 knock-down. 
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Approximately ~9% of the genes on the microarray (3912 genes) showed changes in 
expression and could be clustered into five groups (using SOTA algorithm in MeV, Figure 3.17 
B). Interestingly, of these genes, only ~11% were up-regulated and 19% down-regulated 
together in both knock-downs when compared with the control cells (Figure 3.17 C). This 
indicates that the majority of genes respond differently to MLL1 or Msk1 knock-down, 
suggesting they are regulated differently.  
In order to understand which cellular processes are affected by the knock-down of MLL1 and 
Msk1, the genes were functionally annotated using DAVID.  DAVID is a biological data-base 
and analytical tool, which compares a gene list in a list to the data base in order to correlate 
the genes to known biological functions (Huang et al. 2008). The gene list for each cluster 
was analysed individually and only genes with a FDR (false-discovery-rate) of lower than 15% 
were considered (Figure 3.18 and 3.19). This identified five clusters: 
In cluster 1 genes were grouped which were down-regulated in only Msk1 knock-down cells. 
These genes were functionally enriched with the cell cycle, chromosome condensation and 
DNA repair.  
Cluster 2 contains genes which were up-regulated in only MLL1 knock-down cells. Although 
280 genes were in this cluster, only 66 genes could be connected to a specific function (eg. 
21 genes to cellular stress-response). This suggests that these changes in gene expression 
were indirect responses to the changes in the cell, or are unlikely to be a coordinated 
response to the knock-down. 
In cluster 3 genes were down-regulated in both MLL1 and Msk1 knock-down cells. Most of 
these genes were involved in regulation of MAPK activity (81 genes), the immune response 
(57 genes) and related functions (e.g. cytokine activity, 16 genes). MAPKs are known to have 
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a regulatory influence on the immune response (Liu, Shepherd, & Nelin, 2007;  Arthur & Ley, 
2013), so the down-regulation of these genes in Msk1 knock-down cells is expected. This 
also supports a co-regulatory function of MLL1 and Msk1. However, a large number of these 
genes are also annotated with cellular maintenance (e.g. sugar/lectin binding, 42 genes).  
Cluster 4 genes were up-regulated in Msk1 knock-down cells and were found to be related to 
MLL1 and Msk1 function. For example histone protein genes (79 genes), transcription 
associated genes (72 + 55 + 33 genes) or protein kinases (15 genes) were up-regulated. This 
could be a cellular reaction to compensate for the loss of Msk1, which is an important kinase 
and involved in many cellular processes.  
Finally, cluster 5 genes were up-regulated in MLL1 and Msk1 knock-down cells. These genes 
were all associated with cellular maintenance (e.g. homeostatic processes, 35 genes).  
In order to verify the microarray findings, qPCR analysis of selected genes were performed to 
confirm their up- or down-regulation. Two candidate genes, which were up-regulated and 
two, which were down-regulated in each knock-down were chosen. For the MLL1 knock-
down Il1b and Ly9 (down-regulated) and Hemt1 and Hsph1 (up-regulated) and for the Msk1 
knock-down Ttk and Kif20b (up-regulated) and Ifnar2 and Tet3 (down-regulated) were 
examined. The results are shown in Figure 3.20 and confirmed the microarray data.  
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Figure 3.18: Cluster and gene annotation analysis I. Each gene cluster was then analysed with DAVID, a tool 
for functional annotation of gene lists.  The changes in gene expression in the cluster is shown in the left 
box and the associated annotations with their corresponding hits in the right box (false discovery rate cut-
off: 15%, Enrichment>1.5). Significant biological associations and the number of genes involved are shown. 
Plots indicate the range of gene expression changes between control (1-3), MLL1 KD (1-4) and Msk1 KD (1-
3)  data set. The purple line indicates the average. 
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Figure 3.19: Cluster and gene annotation analysis II. Each gene cluster was then analysed with DAVID, a 
tool for functional annotation of gene lists.  The changes in gene expression in the cluster is shown in the 
left box and the associated annotations  with their corresponding hits in the right box (false discovery rate 
cut-off: 15%, Enrichment>1.5). Significant biological associations and the number of genes involved are 
shown. Plots indicate the range of gene expression changes between control (1-3), MLL1 KD (1-4) and Msk1 
KD (1-3) data set. The purple line indicates the average. 
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Figure 3.20: Validation of microarray data by qPCR. To validate the gene up-/down-regulation data from 
microarray analysis, gene expression changes in Msk1 and MLL1 knock-down cells were analysed by qPCR. 
Two genes that were up-regulated (Hemt1 and Hsph1) and two that were down-regulated (Il1b and Ly9) in 
MLL1 knock-down cells, furthermore, two genes that were up-regulated (Ifnar2 and Tet3) and two that were 
down-regulated (Ttk and Kif20b) in Msk1 knock-down cells, were tested. Graphs indicate transcript 
abundance normalized to β-actin and indicate +/- SD (n=3). All changes were statistically significant (paired    
t-test, p<0.05). Data were normalised to gene expression levels in control cells (Control=1).  
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This analysis characterised the changes in gene expression induced in response to the knock-
down of MLL1 and/or Msk1. In general, annotated genes reflected MLL1- and Msk1-related 
functions (eg. cellular response to stress, cluster 2).  Notably, it seemed that the Msk1 knock-
down had a more dramatic effect on gene expression than MLL1: 543 were down- and 1883 
up in Msk1 knock-down cells, whereas only 280 genes changed expression upon MLL 
knockdown. This may reflect the extent of knock-down, as MLL knock-down was less 
efficient than Msk1, however, a large number of affected genes were not annotated with a 
specific function in DAVID, indicating a limitation of this type of analysis. Finally DAVID 
cannot distinguish between changes in gene expression in direct response to the knock-
down and indirect effects which reflect secondary and tertiary changes resulting from the 
initial response. 
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3.3.5 Changes of histone modifications on MLL1 target genes in MLL1 and Msk1 knock-
down cells 
We established that knock-down of MLL1 and Msk1 induces changes in gene expression at a 
large number of genes with a diversity of cellular functions.  As MLL1 works as a 
transcriptional activator by modulating histone modification, we then examined if down-
regulation of MLL1 or Msk1 would induce changes in the histone modification of target loci. 
Previous studies showed that MLL1 deposits H3K4me3 (Wang et al. 2009) and is stimulated 
by H3K9ac/S10p in vitro (Nightingale et al. 2007). MLL1 is a mammalian trithorax protein 
(TRX), regulators which are counter-acted by polycomb proteins (PCG), which deposit 
H3K27me3. For these reasons, these three marks were examined on the MLL1 target genes 
HoxA 4 and 5 in context of MLL1 or Msk1 knock-down cells. These genes were chosen 
because they showed large reductions in RNA levels in MLL1 and Msk1 knock-down cells 
(Figure 3.15) and we assumed that any changes in histone modifications would be the 
easiest to detect at these loci.  
In order to study the distribution of modifications, a carrier Chip (CChIP) approach was used, 
as this technique requires a small number of target cells (i.e. 1x105), in this case knock-down 
cells. Target cells were mixed with SL2 Drosophila cells to bulk up the cellular material and 
minimise the loss of target chromatin during the procedure. It was important to use a 
Drosophila cell line as this prevents non-specific amplification of the carrier at the end of the 
ChIP procedure. Cells were processed similar to native ChIP, allowing the digestion of 
chromatin with micrococcal nuclease, which resulted in chromatin fragments between 
~100bp and ~500bp (Figure 3.21) 
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Figure 3.21: Chromatin Isolation from knock-down cells. For the ChIP analysis, knock-down cells were 
mixed with Drosophila SL2 cells (“carrier cells”) and the chromatin was digested with micrococcal nuclease, 
resulting in the typical ‘chromatin ladder’.  Mono-di- and tri-nucleosomes are labelled, as is a 100bp ladder. 
S1, S2 and P are fractions of chromatin obtained during the chromatin precipitation procedure (see Chapter 
2.4.5 Carrier Chromatin Immuno-precipitation). Only S1 and S2 were used for immuno-precipitation. 
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This allowed higher resolution analysis of the target genes than using cross-linked 
chromatin, which normally generates ~500bp fragments. In Figure 3.22 A and 3.23 A, the 
primers for HoxA4 and 5 are shown. These were designed to amplify a reference area at the 
promoter 5’ to the TSS (primers 1), to amplify the TSS (primers 2), or an intra-genic region at 
the end of at the gene (primers 3). All primers were tested prior to the experiment for 
specificity to murine DNA.  
In Figure 3.23 B the results for the ChIP on HoxA4 are shown. As expected, H3K4me3 levels, 
both 5’ (HoxA4.1) or at the end of the gene (HoxA4.3), are low and are not altered in the 
different cell conditions. In contrast, a peak of this mark is seen over the TSS in control cells 
and is reduced in MLL1 (-40%) and Msk1 (-50%) knock-down cells. T-test analysis indicates 
this is a significant decline in both MLL1 (p=0.040) and Msk1 knock-down cells (p=0.010) 
A similar pattern of enrichment is seen for H3K9ac/S10p, with low levels of H3K9ac/S10p in 
the upstream region and at the end of the gene. Likewise, enrichment was observed over 
the TSS in the mock-transfected cells, which was diminished in MLL1 (-50%, p=0.009) and 
Msk1 (-40%, p=0.010) knock-down cells. 
Finally, no enrichment of H3K27me3 was observed either 5’ or 3’ to the gene, or over the 
TSS. Interestingly a small increase in this mark (ca. 1.5 fold), which is significant (p=0.005) is 
seen in MLL1 knock-down cells. In Msk1 knock-down cells the same trend was observed 
(p=0.046). 
Similar results were seen for HoxA5 (Figure 3.23 B). H3K4me3 abundance is low both 
upstream (HoxA5.1) and at the end of the gene (HoxA5.3) in the different cells. However, 
over the TSS (HoxA5.2) an enrichment of H3K4me3 was observed in control cells, which was 
reduced in MLL1 (-60%, p=0.003) and Msk1   (-50%, p=0.002) knock-down cells.  
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Similarly, for H3K9ac/S10p, an enrichment over the TSS observed in mock-transfected cells, 
was diminished in MLL1 (-50%, p=0.014) and Msk1 (-40%, p=0.019) knock-down cells. 
Finally, no enrichment of H3K27me3 was observed upstream (5’) or the end of the gene 
under the different cell conditions. Over the TSS no enrichment was observed in mock-
transfected cells, but in knock-down cells a small increase in H3K27me3 levels were seen. 
However these changes were not statistically significant (MLL1 p=0.413 and Msk1 p=0.183). 
In general, these experiments show that knock-down of MLL1 and Msk1 changes the histone 
modification landscape at MLL1 target genes. Furthermore, the changes in MLL1 knock-
down cells were analogous to those in Msk1 knock-down cells. Moreover it confirmed the 
antagonistic action of the trithorax (i.e. H3K4me3 and H3K9ac/S10p levels down) and 
polycomb group proteins (ie. H3K27me3 up) at these MLL1 targets. These findings support 
the hypothesis that MLL1 and Msk1 work in concert to regulate gene expression using 
epigenetic mechanisms. 
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Figure 3.22: Effect of MLL1 and Msk1 knock-down on H3K4me3, H3K27me3 and H3K9ac/S10p distribution 
at HoxA4. (A) Gene map for HoxA4 (boxes = exons). Primers were designed to screen multiple sites on the 
HoxA4 gene (representative MLL1 target gene). (B) MEFs were transfected with a Msk1 or a MLL1 knock-
down construct. After 20 hours the cells were harvested and CChIP analysis of H3K4me3, H3K27me3 and 
H3K9ac/S10p was performed. Graphs present these modifications at three sites over the HoxA4 gene, with 
the abundance in mock transfected cells normalized to 1.0. Red asterisks mark significant changes in 
modification levels (paired t-test, p<0.05*, p<0.01**, p<0.001 ***). 
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Figure 3.23: Effect of MLL1 and Msk1 knock-down on H3K4me3, H3K27me3 and H3K9ac/S10p distribution 
at HoxA5. (A) Gene map for HoxA5 (boxes = exons). Primers were designed to screen multiple sites on the 
HoxA5 gene (representative MLL1 target gene). (B) MEFs were transfected with a Msk1 or a MLL1 knock-
down construct. After 20 hours the cells were harvested and CChIP analysis of H3K4me3, H3K27me3 and 
H3K9ac/S10p was performed. Graphs present these modifications at three sites over the HoxA5 gene, with 
the abundance in mock transfected cells normalized to 1.0. Red asterisks mark significant changes in 
modification levels (paired t-test, p<0.05*, p<0.01**, p<0.001 ***). 
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3.4 MLL1 and Msk1 during the cell cycle 
 Previous studies have linked MLL1 to cell cycle regulation and our analysis of the 
distributions of MLL1 and Msk1 binding indicated that both proteins bind to genes, which 
are functionally linked to the cell cycle (see Chapter 3.3, Figure 3.18 and 3.19).  This argues 
for a regulatory impact of MLL1 and Msk1 on the cell cycle, however, previous reports 
disagree about MLL1 function during the cell cycle. Several studies suggest that MLL1 may 
have an active role in cell cycle progression. For example MLL1, in concert with menin, has 
been shown to regulate cyclin-dependent inhibitors (Milne et al. 2005). This was consistent 
with observations that MLL1 abundance oscillates throughout the cell cycle, with peaks in 
G1/S and M-phase, but remains associated with chromatin even at its lowest levels  during 
mitosis (Caslini et al. 2000; Liu et al. 2007).  In contrast, another study showed that MLL1 is 
displaced during mitosis (Ennas et al. 1997) and that H3K4me3, although still found in 
condensed chromatin, changes dynamically during the cell cycle (Mishra et al. 2009). More 
recently, it has been suggested that MLL1 retention at gene promoters during mitosis 
accelerates transcription reactivation following mitotic exit (Blobel et al. 2009).  Taken 
together, there is controversy whether MLL1 is displaced during mitosis and MLL1’s impact 
on cell cycle progression. Therefore we examined the dynamics of MLL1 and Msk1 during 
the cell cycle, focussing on their association to chromatin as well as the dynamics of key 
histone modifications associated with the MLL1 complex.  
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3.4.1 Elutriation of LCLs 
Elutriation is a technique to separate particles, which are in suspension, according to their 
size. As shown in Figure 3.24 A, a specialized elutriation rotor is needed. In this rotor an 
elutriation chamber is fitted. The rotor is spun at a constant speed, which is dependent on 
the average cell size, creating a centrifugal force. Cells are injected in a constant flow of 
buffer, which can be adjusted by altering the pump speed. The cells thus move with the fluid 
through the elutriation chamber, creating a counter flow to the centrifugal force (Figure 3.24 
B).  The cells initially enter the chamber with a lower flow rate, which loads them into the 
chamber (Figure 3.24 B). In this stress field of two counteracting forces the cells are aligned, 
with the bigger cells accumulating at the bottom of the chamber and the smaller ones 
towards the exit. By increasing the pump speed, the flow rate of the buffer can be increased 
and this drives the cells out of the chamber and different fractions can be collected  (Grant & 
Morrison 1979; Banfalvi 2011).  
In the different stages of the cell cycle the cells vary in size (e.g. G1 cells are smaller than G2 
cells), therefore elutriation can be used to isolate fractions of cells at different stages of the 
cell cycle (Kauffman et al. 1990). However, the shape of the cells can influence their 
streaming behaviour. For this reason, the elutriation buffer contains a relatively low salt 
concentration (0.75 x PBS), which causes the cells to swell up and adopt a rounder 
morphology equalizing irregularities on the cell surface. The elutriation buffer also contained 
BSA and EDTA to prevent cells sticking to each other, or the walls of the elutriation system. 
In this study we used LCLs, a human lymphoblastoid cell line with a normal karyotype, that 
grows in suspension and can be cultured in large volumes.  
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Figure 3.24: The elutriation system. (A) During elutriation cells are separated according to their size, 
density and shape. The separating chamber is fixed in a centrifuge and the cells are pumped through it with 
a stream of buffer that runs in the opposite direction of sedimentation. (B) Two opposing forces (the 
centrifugal force and the counter flow) create a force field in the separating chamber, in which the cells align 
according to their characteristics. Generally smaller cells will sediment at the front and bigger ones towards 
the back of the chamber. By increasing the pump speed (=counter flow) cell fractions can be eluted from the 
chamber in a controlled manner (The JE-5.0 Elutriation System, Beckman-Coulter Handbook). 
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LCLs were loaded into the chamber at a pump speed of 11 ml/min. Fractions of 200 ml were 
collected and then the pump speed was increased.  In total five fractions were collected at a 
pump speed of 11.0, 12.5, 14.5, 16.5 and 18.5 ml/min. These were kept on ice during 
collection, before subsequent analysis by FACS analysis to confirm that the cells were in the 
expected cell cycle stage.  In Figure 3.25, a representative FACS analysis of one elutriation 
run is shown.  In the top panel, a FACS profile of unsorted LCLs is shown (Asynchronous). In 
this sample ~42% of the cells were in G1 (red box) and only ~16.5% were in G2/M (blue box).  
In the first collected fraction (Fraction 11.5 ml/min, Panel 2) ~67% of the cells were in G1 
and ~12% in G2/M. With increased pump speed the number of G1 cells decreases and the 
number of G2/M cells increases. In the last collected fraction (Fraction 18.5 ml/min, Panel 6) 
only ~11% of the cells were in G1 and ~70% of the cells were in G2/M.  For further analysis 
the 11.5 ml/min (G1) and the 18.5 ml/min (G2/M) fractions were collected and compared to 
unsynchronized LCLs. In the initial experiments the LCLs were untreated. However, when 
examining the G2/M phase under the microscope, only ~10 % of the cells in the fraction 
were actually in M-phase. In order to increase the proportion of cells in mitosis, LCLs were 
treated with colcemid for 3 hours prior to sorting, which increased the proportion of cells in 
M-phase to ~30% (Data not shown).  
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Figure 3.25:  Representative FACS analysis of elutriated cells. The collected cell fractions were 
dependent on the pump speed (11-18.5 ml/min). Cells were treated with propidium iodide, which stains the 
DNA quantitatively, and FACS analysed. Graphs indicate cell number (y-axis) against PI fluorescence/cell 
ploidy (x-axis). The cell-cycle profiles are shown, with G0/G1 cells gated in the red box and G2/M cells in the 
blue box. In the table the proportion of cells in these cell cycle stages are shown. A sample of cells was taken 
before elutriation (Asynchronous) for reference. Generally the cell fraction harvested at 11 ml/min was used 
as the G1 sample and the cell fraction harvested at 18.5 ml/min as the G2/M sample. 
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3.4.2 Analysis of MLL1 and Msk1  
In the first part of the analysis, fractions were collected and cell lysates prepared for western 
analysis, to examine cell-cycle dependent changes in MLL1 or Msk1 abundance. In Figure 
3.26 A, a representative western blot is shown. We loaded an asynchronized sample, a G1- 
and a G2/M-enriched sample and subsequently probed for MLLN, Msk1-p and β-Actin, which 
acted as a loading control.  However, no significant changes were detected. In 3.26 B the 
quantitated and normalized results of three experiments are shown, confirming that both 
proteins had stable levels throughout the different stages of the cell cycle.  
In a second part of this analysis, we examined the association of the two proteins with 
chromatin at different stages of the cell cycle. We used immuno-fluorescence microscopy to 
visualize the binding of these proteins in cells in G1 (Figure 3.27) and on mitotic 
chromosomes (Figure 3.28). In order to eliminate non-specific binding of the secondary, 
fluorescence-labelled antibody, we performed a no-primary antibody control (Figure 3.27 A 
and 3.28 A). No non-specific signal was detected either on cells in G1, or on mitotic 
chromosomes. In G1 cells, MLL1 and Msk1 show a strictly nuclear location, as their binding 
corresponded to the counter staining of the DNA with DAPI. Both proteins bind throughout 
the nucleus with no specific prevalence. A similar situation was observed on mitotic 
chromosomes. MLL1 and Msk1 bind with an ‘overall’ coverage of the chromosomes, 
indicating that the two proteins remain associated with the chromatin, even at its most 
condensed form during mitosis. The red and green stained patches were artefacts, as cell 
debris tends to absorb the secondary antibodies and those patches were not observed on all 
mitotic chromosomes.  
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Figure 3.26: MLL1 and Msk1 abundance during the cell cycle.  (A) Whole cell lysates of cell-cycle enriched 
fractions were analysed by western. The western was probed for MLL1, Msk1-p and for loading control with 
β-Actin. Representative blots are shown (B) The experiment was repeated three times and the westerns 
were quantified. No significant differences in the two cell cycle stages could be detected for MLL1 or Msk1. 
Significant changes are marked with asterisks (paired t-test, p<0.05*, p<0.01**, p<0.001 ***). 
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Figure 3.27: Nuclear distribution of MLL1 and Msk1 in G1 phase. (A) Secondary antibody specificity control. 
DNA was counter-stained with DAPI (left).  Cells in G1 phase were stained with the secondary α-mouse IgG 
(red, middle) or α-rabbit IgG (green, right) antibody to check for non-specific cross reactions. (B) Cell cycle 
specific fractions were collected and prepared for immuno-fluorescence microscopy. Red=MLL1, 
Green=Msk1, Blue=DAPI (100 x magnification).   
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Figure 3.28: MLL1 and Msk1 distribution on mitotic chromosomes. (A) Secondary antibody specificity 
control. DNA was counter-stained with DAPI (left). Cells in M-phase were stained with the secondary α-
mouse IgG (red, middle) or α-rabbit IgG (green, right) antibody to check for non-specific cross reactions. (B) 
Cells fractions were collected and immediately prepared for Immuno-fluorescence microscopy.  
Chromosome 1 is shown enlarged. Red=MLL1, Green=Msk1, Blue=DAPI (100 x magnification).   
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3.4.3 Analysis of histone modifications 
In a subsequent analysis, we examined the global changes in histone modification 
abundance involved in MLL1 function in the different stages of the cell cycle. Histones were 
acid-extracted and analysed by western blotting. We examined the ‘active marks’ H3K4me3 
and H3K9ac, which are deposited by components of the MLL1 complex (Slany 2009a) and 
analysed H3K27me3, a ‘silencing mark’, deposited by Polycomb proteins, as PRC2 (polycomb 
repressive complex 2) is proposed to be activated by dense chromatin (Yuan et al. 2012).  
Furthermore H3S10p was examined as mitotic chromatin is  marked with this modification 
(Hsu et al. 2000; Hauf et al. 2003) and therefore functioned as an internal control. Finally 
H3K9acS10p was examined because this modification stimulates the SET activity of MLL1 
(Nightingale et al. 2007). Western blots were labelled with an anti-histone H3 C-terminal 
antibody, which was used as a loading control. Representative westerns are presented in 
Figure 3.30 A and the results of three individual experiments, which were normalized to an 
unsorted, asynchronous cell population, are shown in Figure 3.30 B. We found  H3K4me3 
abundance is  comparable  in the G1  and the G2/M  cells, as were H3K27me3  and  for 
H3K9ac. In contrast, H3K9ac/S10p was significantly elevated in G2/M (~+ 35%, paired t-test: 
p=0.049) and as expected, H3S10p levels were highly elevated in G2/M cells (~+170%, paired 
t-test: p=0.000).   
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Figure 3.29: Histone modification abundance during the cell cycle.  (A)  Histones were extracted from cell-
cycle enriched fractions and analysed by western. The western was probed for key MLL-related histone 
modifications. Histone H3 C-terminal was used as a loading control. Representative blots are shown. (B)  The 
experiment was repeated three times and the westerns quantified. Most histone modifications showed no 
differences in the different cell cycle stages. Only H3S10p showed enrichment during G2/M. Significant 
changes are marked with asterisks (paired t-test, p<0.05*, p<0.01**, p<0.001 ***).  
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In a first analysis we explored the pattern of histone modification on the chromatin in G1 
and mitotic cells using immuno-flourescence-microscopy [Figure 3.30 (H3K4me3 and H3K9ac 
in G1), Figure 3.31 (H3K27me3 and H3S10p in G1), Figure 3.32 (H3K4me3 and H3K9ac in M-
phase) and in Figure 3.33 (H3K27me and H3 S100 in M-phase)].   
In G1 phase H3K4me3, H3K27me3 and H3K9ac are associated with the chromatin 
throughout the  nucleus. However, whilst H3K9ac showed an ‘all-over’ distribution, 
H3K4me3 and H3K27me3 showed a ‘speckled’ distribution with binding hotspots that do not  
correlate with DAPI dense regions. H3S10p was less abundant in the nucleus and showed 
concentration to a few areas. 
 On the mitotic chromosomes H3K4me, H3K27me3 and H3K9ac  bind in distinct patterns to 
the chromosomes, revealing highly methylated or acetylated areas, which have been 
described in detail previously (Terrenoire et al. 2010). The H3K4me3 and H3K9ac banding 
pattern seem to correlate. For example on chromosome 1, which is shown enlarged in Figure 
3.31, a highly stained pole on the top of the p-arm, a distinctive band on the q-arm right 
beneath the centromere and diffuse staining on the q-arm for both modifications are 
observed. In contrast, H3K27me3 showed a  distinctivly different distribution. The pole of 
the p-arm is highly stained, several weaker bands on the p- and the q-arm can be observed 
and only the  centromere is depleted completely of H3K27me3. Finally H3S10p is detected 
all over the chromosome, with highly stained caps on the p- and the q-arm and the 
centromere.  
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 Figure 3.30:  H3K4me3 and H3K9ac distribution in G1 phase cells. Cells fractions were collected and 
prepared for immuno-fluorescence microscopy. Green=indicated histone modification, Blue=DAPI 
(Magnification: 100x). 
118 
 
 
 
Figure 3.31: Histone modifications on mitotic chromosomes. Cells fractions were collected and 
immediately prepared for Immuno-fluorescence microscopy. Chromosome 1 is shown enlarged. 
Red/Green=indicated histone modification, Blue=DAPI (Magnification: 100x). 
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Figure 3.32: H3K4me3 and H3K9ac distribution on mitotic chromosomes. Cells fractions were collected and 
prepared for immuno-fluorescence microscopy. Chromosome 1 is shown enlarged. Green=indicated histone 
modification, Blue=DAPI (Magnification: 100x). 
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Figure 3.33: H3K27me3 and H3S10p distribution on mitotic chromosomes. Cells fractions were collected 
and prepared for immuno-fluorescence microscopy. Chromosome1 is shown enlarged. Red/Green=indicated 
histone modification, Blue=DAPI (Magnification: 100x). 
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Taken together, we have shown that the MLL1 and Msk1 abundance does not change in G1 
or G2/M and is comparable to the protein levels found in unsynchronized cells. Furthermore, 
MLL1 and Msk1 were associated with chromatin in G1 as well as with mitotic chromosomes, 
the most condensed form of chromatin. Neither proteins show any local preferences on the 
chromatin, but bind throughout equally the chromatin in G1 and on the chromosomes. 
Likewise, H3K4me3, H3K9ac and H3K27me3 do not show any differences in abundance in 
any stage of the cell cycle, but the distribution pattern changes (from an overall binding to 
chromatin in G1, to specific banding patterns on chromosomes). H3S10p was  noticeably 
different.  It showed a vast upregulation during G2/M on both western blots and microscopy 
slides. In G1  cells the mark showed localization to discrete areas, while on mitotic 
chromosomes the mark was found all over them. Interestingly H3K9acS10p was elevated in 
G2/M cells, but not in G1. However, the antibody was not suitable for microscopy analysis 
and therefore no conclusion on its distribution in chromatin can be made.  
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4 Discussion 
Chromatin and histone modifications play an important role in many physiological, cellular 
processes, like development (Pengelly et al. 2013),  response to external stimuli (Tittel-Elmer 
et al. 2010) and disease (Burke & Bhatla 2014). It has been established, that certain histone 
modifications are associated to certain gene activation states. For example acetylation and 
tri-methylation of histone H3K4 are associated with the active gene state and tri-methylation 
of histone H3K27 with a repressive gene state (Kouzarides 2007). A large number of proteins 
are known to deposit (‘writer’), remove (‘eraser’) or recognise (‘reader’) specific histone 
modifications, with crucial functions in physiological or pathological contexts (Jakovcevski & 
Akbarian 2012).  
 
4.1 Epigenetic regulation by MLL1 
The histone methyltransferase MLL1 (mixed lineage leukaemia 1) is an epigenetic writer 
protein, which is often mutated in leukaemia, especially in childhood acute myeloid 
leukaemia (AML) (Krivtsov & Armstrong 2007).  Studies with MLL1-/- mice have shown that 
the homozygous knock-out of MLL1 is embryonically lethal, making MLL1 an essential 
epigenetic modifier (Hess et al. 1997). The MLL1 protein functions within a large multi-
protein complex, which regulates the degree of histone H3K4 methylation deposited at 
target genes (Patel et al. 2009), however it is not yet known how MLL1 is targeted to its sites 
(Ansari & Mandal 2010). The SET domain of MLL1 is primarily a mono-methyltransferase and 
only in collaboration with the conserved group of WARD proteins (WDR5, Ash2L, RbBP5 and 
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DPY-30) H3K4me1 can be sequentially catalysed further (Dharmarajan & Cosgrove 2009). 
Although these proteins form the MLL1 core complex and are essential for proper histone 
H3K4 methylation in vitro, many more proteins (~30) have been associated with the MLL1 
complex (Nakamura et al. 2002). The complete MLL1 complex acts on chromatin by 
methylation and acetylation (Slany 2009).  In MLL1-associated leukaemias the MLL1 protein 
is disrupted by chromosomal translocation, which leads to the formation of fusion-proteins 
and a disruption of the MLL1 protein complex (Ford, 1993). The C-terminus of MLL1 is lost 
and with it the SET domain, resulting in the a mis-regulation of MLL1 target genes (Ayton & 
Cleary 2003). Well known MLL1 target genes are the Hox genes, which are key transcription 
factors during development and haematopoiesis (Hess et al. 1997; Jude et al. 2007). 
MLL1 is a mammalian Trithorax protein, which in concert with Polycomb proteins regulate 
their target genes by methylation of chromatin. Trithorax proteins deposit the ‘activating’ 
H3K4me3 mark and Polycomb proteins deposit the ‘silencing’ H3K27me3 mark, antagonizing 
each other’s function (Steffen & Ringrose 2014). Here we examine the role of Msk1, a 
histone kinase, as a potential member and co-regulator of the MLL1 complex. 
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4.2 Is the Histone kinase Msk1 involved in MLL1 regulation? 
Msk1 (mitogen-and-stress-induced kinase1)  is a downstream kinase of the MAPK pathway 
(Deak et al. 1998), which phosphorylates either transcription factors or histones (Duda  
2012).  It has been shown, that Msk1 is involved in the activation of immediate-early (IE) 
genes (Thomson et al. 2001) and it has been suggested, mainly based on work in yeast, that 
MAPKs might be functional components of transcriptional complexes, which might recruit 
additional factors to chromatin (Alepuz et al. 2001; Thomson et al. 2001). 
The findings, (I) that phosphorylation stimulates MLL1’s SET activity (Nightingale et al. 2007), 
(II) that Msk1 induced phosphorylation lead to a loss of Polycomb-mediated gene silencing 
(Lau & Cheung 2011), (III) that Msk1 is  involved in the activation of IE genes (Drobic et al. 
2010) and (IV) that in yeast, MAPKs can be part of transcriptional complexes (Edmunds & 
Mahadevan 2004), lead to the hypothesis, that Msk1 is involved in the regulation of MLL1 
activity.  
Here we tested this hypothesis. In the first set of experiments the interaction of MLL1 and 
Msk1 was explored. These experiments were complemented with an analysis of the genomic 
distribution of MLL1 and Msk1, followed with a third set of experiments, which examined 
the functional impact of MLL1 and Msk1 on gene activity. A final experiment examined 
changes in MLL1 and Msk1 abundance and key histone modifications during the cell cycle. 
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4.3 Do MLL1 and Msk1 physically interact?  
MLL1 forms a multi-subunit complex and many proteins have been found to interact with it 
(Nakamura et al. 2002).  One possibility how Msk1 might contribute to MLL1 regulation is by 
directly interacting with MLL1 and even be a component of the complex. To address this, co-
immunoprecipitation experiments were carried out. However, both proteins are known to 
bind to chromatin. Therefore it needed to be considered that MLL1 and Msk1 might not 
interact directly, but might bind to adjacent sites in chromatin.  Initial experiments were 
carried out in a human cell line. It showed that MLL1 and the phosphorylated, active form of 
Msk1 can be pulled down together (Figure 3.2). In order to release chromatin-bound 
proteins from the DNA, ethidium bromide was added to the lysis buffer but the proteins still 
efficiently co-immumoprecipitated. This indicated a direct interaction between MLL1 and 
Msk1, which was independent of chromatin. However, pull-downs with MLL1 and non-
phosphorylated Msk1 were not as conclusive. Although Msk1 was detected in the MLL1 pull-
down, MLL1 was not detected in the Msk1 pull-down.  This can be interpreted in two ways: 
It might be that MLL1 interacts preferably with the activated Msk1, but not with the un-
phosphorylated, inactive form. It is also possible that this specific epitope is important for 
MLL1/Msk1 interaction, which the bound antibody interrupts.  In order to extend these 
findings co-IP experiments were repeated in other cell types (human and mouse), which 
confirmed the interaction of MLL1 and phosphorylated Msk1. A potential problem with co-IP 
experiments is the non-specific protein binding to the IP antibody and/or the beads. 
Although the cell lysate was pre-cleared and the beads were washed with higher ionic 
strength buffer to disrupt non-specific binding, some back-ground has to be expected. We 
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observed antibody contamination, showing up as a ~25kDa (light chain) or a ~50kDa (heavy 
chain) on a SDS gel, as seen in Figure 3.2, that obscure the results. 
To examine the question from another angle, FLAG-tagged MLL1 was over-expressed in 
HEK293 cells and then purified using beads, to which anti-FLAG-antibodies were cross-linked. 
The FLAG-tag is a small peptide (DYKDDDDK), which was engineered not to disturb the 
protein function of the tagged protein and to prevent non-specific binding. Here the FLAG-
tag was fused to the N-terminus of MLL1 and introduced into the cells using a gentle 
transfection method (no cell death occurred). Cells were lysed and the protein precipitated, 
washed with low-ionic strength buffer and eluted with 3xFLAG peptide, to ensure the 
integrity of the MLL1 complex. Complex purity was characterized by gel-filtration.  Although 
the sample contained a lot of small protein contamination (Figure 3.5 C), a single peak in the 
FLAG-prep (Figure 3.5 C, indicated with *) was observed, corresponding to a large molecular 
weight complex. This peak corresponded to a complex of several large moleculat weight 
proteins (Figure 3.5 A, indicated with arrow). For western analysis the complex was run on a 
4-12% gradient gel to obtain better separation of the complex components. The membrane 
was probed with anti-FLAG, anti-Msk1p and anti-NFκB antibody. NFκB (a strong interaction 
partner of Msk1 (Vermeulen et al. 2003)) was only found in the input suggesting that the 
protein complex did not contain non-specific proteins. FLAG-MLL 1 protein and the 
phosphorylated Msk1 were also found in the complex, suggesting that Msk1 is a stable 
member of the MLL1 complex. However, to confirm this, a large amount of MLL1-complex 
needs to be purified and separated over the gel-filtration column, so that components can 
be characterized by mass-spectroscopy. Furthermore, these results do not reveal if Msk1 is a 
permanent member of the MLL1 complex or if this is a transient interaction. 
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4.4 Do MLL1 and Msk1 bind to the same genomic sites? 
The first set of experiments indicated that MLL1 and phosphorylated Msk1 interact with 
each other and that Msk1 might be a member of the MLL1 complex. This suggested that the 
two proteins would be found at the same genomic sites. We addressed this directly by cross-
linked chromatin immunoprecipitation. Proteins were cross-linked to chromatin and MLL1 
and phosphorylated Msk1 were immunopreciptiated. The bound DNA was inserted into 
libraries for high-throughput sequencing on the Illumina Next-generation HiSeq2000 
Sequencing platform. Direct comparison of the distribution of MLL1 and Msk1 binding 
showed an overlap of MLL1 and Msk1 binding sites at a third of binding sites (~35%). These 
binding sites were compared with H3K4 tri-methylation of histones, which showed a small 
correlation of H3K4me3 with MLL1 and Msk1 (~2% overlap). A trend-plot over transcription 
start sites (TSS) revealed a peak of MLL1 and Msk1 over the TSS, substantiating the 
proposition that Msk1 is a member of the MLL1 complex. The scatterplot analysis, which 
compared MLL1 and Msk1 binding strength at their shared binding sites, showed a strong 
correlation for their binding  signals, which strengthens the hypothesis 
Functional annotation analysis of these genes with DAVID did not reveal unique groups of 
genes. Only three groups (Translation, 3 counts, 0.37 fold enrichment; Regulation of 
transcription, 4 counts,  0.21 fold enrichment; Phospho-protein, 10 counts, 0.17 fold 
enrichment) were flagged, but they all had quite low enrichments and a high false-discovery-
rate (FDR ~32) and were therefore not statistically significant.  
Nevertheless, it was shown that MLL1 and Msk1 bind to a number of sites in the genome 
and can be found at a subgroup of binding sites. These findings support the hypothesis that 
Msk1 can be a member of the MLL1 complex. 
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4.5 What is the functional impact of MLL1 and Msk1 interaction? 
Having established an interaction between MLL1 and Msk1, the functional impact of this 
interaction was examined by knocking these regulators down in vivo. A transient knock-
down in primary cells was chosen, as they would best represent the early changes in gene 
transcription in a physiological context. This was also the only way to do the experiment as   
the transfected cells started to die at around day 2 post-transfection and stable knock-
downs in CCEER (embryonic stem cell line) for MLL1 or Msk1 were not viable. However, 
while the Msk1 knock-down resulted in substantial reduction in protein levels (reduced by 
~99%), MLL1 levels were not reduced by more than ~63%. Even after three days post knock-
down, when ~70% of the transfected cells were dead, MLL1 levels remained stable, 
indicating that lower levels of MLL1 cannot be tolerated. Therefore cells with partial knock-
down of MLL1 were used for further experiments.  
Initially we examined the impact of knock down at known MLL1 target genes. The HoxA 
genes were chosen as they are important genes in development and haematopoiesis and are 
known to be de-regulated in leukaemia. This showed a significant reduction in gene 
expression for most HoxA genes, especially those in the middle of the cluster (HoxA 2-11), an 
effect seen in both knock-downs. These findings suggest that both MLL1 and Msk1 
contribute to HoxA gene regulation.  It is known that Hox genes are regulated in clusters and 
that genes in a cluster can cross-regulate each other, leading to the effect of collinearity 
(Montavon & Duboule 2013). Apparently MLL1 and Msk1 binding and H3K4 methylation at a 
few sites in the HoxA cluster is sufficient to regulate the majority of the cluster. The 
expression of the oncogene Meis1, which is often mis-regulated in leukaemias was also 
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examined, but no changes in expression were found, suggesting that MLL1/Msk1 do not 
regulate this gene.  
As we have shown previously, MLL1 and Msk1 bind to many sites in the genome, therefore 
in the next experiment the global impact of MLL1 and Msk1 on gene regulation was 
examined using microarray analysis. Although 3912 genes changed their expression in MLL1 
or Msk1 knock-down cells, only 11% of these genes were down-regulated in both MLL1 and 
Msk1 knock-down cells and only 19% were up-regulated together.  The majority of genes 
showed different responses to MLL1 or Msk1 knock-down. This could have a number of 
reasons. (I) Msk1 modifies chromatin, but also transcription factors and is known to bind to 
other proteins, like NFκB or CREB (Arthur 2008). It is therefore likely that Msk1 knock-down 
would also functionally impact other genes beyond MLL1 targets. In fact 63% of the 
responding genes change their expression only in the Msk1 knock-down. (II) The MLL1 
protein levels were only reduced by about 60-70%. As a certain level of MLL1 seems to be 
required for cell survival, it could be that the effect on MLL1 target genes is buffered. (III) 
Finally a number of MLL1 and Msk1 homologues exist in cells. It is possible that these 
proteins are redundant with MLL1 and Msk1 and permit cell functionality.  
Nevertheless, these results showed that down-regulation of MLL1 and Msk1 lead to the 
same response in a significant number of genes, indicating a coordinated action of the two 
proteins.  However, the fact that the majority of gene expression changes occurred only in 
one knock-down cell type (63% of genes only changed in Msk1 knock-down cells) suggest 
that MLL1 and Msk1 do not have an exclusive interaction. This finding is consistent with the 
results of the ChIP-Seq experiments which showed that MLL1 and Msk1 share ~35% of their 
genomic binding sites. 
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As MLL1 and Msk1 are both chromatin modifiers, the impact of their knock-down on key 
histone modification on MLL1 target genes was examined. HoxA4 and 5 were chosen 
because they showed a substantial reduction of transcription levels in knock-down cells 
(Figure 3.15) and we reasoned this would make the detection of changes in histone 
modifications easier. Primers were designed to cover three areas: a control area 5’ to the 
gene, the TSS and a region 3’ at the end of the gene. Levels of histone modification in knock-
down cells were compared to mock-transfected cells. Although the changes were subtle, 
several trends could be detected, some of which were statistically significant. We found 
H3K4me3 and H3K9ac/S10p levels would drop at TSS in knock-down cells, whereas 
H3K27me3 levels would rise. These findings showed the impact of MLL1 and Msk1 gene 
regulation at an epigenetic level. The reduction of HoxA4 and HoxA5 was accompanied by 
the reduction of H3K4me3 (deposited by MLL1) and H3K9ac/S10p (deposited by Msk1 and 
CBP, a member of the MLL1 complex). As a consequence the levels of H3K27me3 (deposited 
by Polycomb proteins counter-balancing Trithorax proteins) showed a trend to increase. This 
transcriptional ON/OFF switch by Trithorax and Polycomb protein has been described for 
other target genes as well, for example at Drosophila’s Ubx gene (Papp & Müller 2006). It 
was found that in the repressive state the Ubx gene was bound by Polycomb proteins and 
tri-methylated at H3K27, whereas in the active state this mark was absent and Trithorax 
protein binding at the promoter was observed in concert with H3K4 tri-methylation at this 
region (Papp & Müller 2006). 
 
131 
 
4.6 Do MLL1 and Msk1 change during the cell cycle? 
The sequencing and microarray experiments indicated that a number of genes, which are 
bound by MLL1 and Msk1 and change their expression in knock-down cells, were associated 
with the cell cycle (Figure 3.21). Furthermore, previous reports associated MLL1 the cell 
cycle. However there has been controversy concerning how MLL1 is regulated. Data suggest 
that MLL1 is either evicted from chromatin during mitosis (Ennas et al. 1997, Mishra et al. 
2009) or that  it  stays on chromatin throughout the cell cycle stages  were it was (Caslini, 
Shilatifard, et al. 2000), and having an active role in cell-cycle regulation (Milne et al. 2005, 
Liu et al. 2007, Blobel et al. 2009). We therefore decided to examine MLL1 and Msk1 protein 
abundance in different cell cycle stages, as well as their association to chromatin. In parallel, 
key histone modifications associated with MLL1 function were examined. In order to 
separate cells in different stages of the cell cycle, elutriation was used, a method, which 
separates cells according to their different size and shape at different cell cycle stages. This 
method has the advantage that cells were treated the same way for the same time.  
We found that on a global level MLL1 and (phosphorylated) Msk1 protein levels in G2/M and 
G1 were comparable to an unsorted cell population (Figure 3.5.3). We subsequently 
analysed cells at a single cell level for MLL1 and Msk1 nuclear occupancy. In G1 the two 
proteins were found throughout the nucleus, indicating even binding of MLL1 and Msk1 
throughout chromatin, which was in accordance with our distribution data. The most 
condensed form of chromatin, metaphase chromosomes during mitosis, were examined and 
showed that MLL1 and Msk1 binding throughout the DNA as well. This indicated that MLL1 
and Msk1 are not excluded from the chromatin during mitosis, however, the resolution of 
the microscope was not high enough to distinguish if MLL1 and Msk1 remain bound to the 
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chromatin or if they align on the outside of the chromosome in the perichromosomal layer 
(chromosome periphery). It has been proposed that this layer may act like a skin protecting 
the chromosome surface and is enriched in nuclear proteins (Ohta et al. 2011). 
We then examined the key histone modifications associated to MLL1 function. At a global 
level, H3K4me3 did not show any differences in G1 and G2/M compared to unsynchronized 
cells (Figure 3.5.6).  Neither did H3K27me3. H3K9ac levels were slightly higher in both G1 
and G2/M, presumably due to gene activity in these cell populations (~60% of G2/M were in 
G2 phase and H3K9 acetylation is a general mark of active transcription). In contrast, H3S10 
phosphorylation levels were highly enriched in G2/M (~+170%). This is consistent with the 
known H3S10p function as a marker of mitotic chromatin (Hsu et al. 2000) and therefore 
functioned as an internal control, as significant changes in histone modifications could be 
detected although only ~30% of the cells in the G2/M population were in mitosis. The dual 
mark, H3K9acS10p, showed no enrichment in G1 cells, but in the G2/M population an 
enrichment of ~35% was observed. When the histone modifications were examined at a 
single cell level by fluorescence microscopy, these showed a shift from an overall 
distribution for H3K4me3, H3K27me3 and H3K9ac with some hotspots in G1 cells, to a 
banding pattern in mitotic chromosomes  that has been described  before (Terrenoire et al. 
2010). In contrast, whereas H3S10p was only found in few areas in G1 cells, mitotic 
chromosomes showed an all-over distribution (Figure 3.32 and 3.32).  No data were 
generated for H3K9acS10p as the antibody was not compatible with immunofluorescence. In 
summary we have shown that MLL1 and Msk1 binding is stable throughout cell cycle and 
that both stay closely associated to chromatin during mitosis. Although H3K4me3 levels 
were not changed in G1 or G2/M, H3K9acS10p levels were up-regulated in mitosis, 
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suggesting this may have a potential role for MLL1 to restart transcription after mitosis. This 
is consistent with proposals that MLL1 functions as a ‘mitotic bookmarker’ (Kadauke & 
Blobel 2013), as MLL1 is bound to chromatin during mitosis and showes a mitosis-specific 
shift in genomic occupancy of MLL1, in favour of genes highly expressed in interphase. Those 
changes should promote rapid transcriptional activation to facilitate M/G1  transition (Blobel 
et al. 2009) . Our results support this hypothesis and suggest that Msk1 might deposit the 
H3K9ac-associated H3S10p mark, which stimulates MLL1’s SET activity and therefore 
promote transcriptional activation. 
4.7 How do the results support our hypothesis? 
The aim of this thesis was to examine whether Msk1 contributes to MLL1 function. As 
discussed, the data indicate that Msk1 is a potential member of the MLL1 complex. Not only 
were they precipitated together, they also correlate to sub-set of genomic sites on 
chromatin. It was further shown that MLL1/Msk1 occupy many sites independently and 
supported by expression studies, which showed that a subset of genes are regulated by both 
MLL1 and Msk1, but the majority of genes are not, suggesting that the MLL1/Msk1 
interaction is not exclusive and that Msk1 regulates genes independently of MLL1. 
Moreover, we show that MLL1 and Msk1 are likely to regulate gene expression by depositing 
histone marks (H3K4me3 by MLL1 and H3K9ac/S10p by Msk1). Finally the elutriation 
experiments indicated that the MLL1 complex (with Msk1) remains associated with 
chromatin during the cell cycle and that, although H3K4me3 is stable throughout the cell 
cycle, the H3K9ac/S10p mark is elevated during mitosis, offering a possible mechanism of 
how MLL1 might promote gene reactivation at the mitosis-interphase change.  
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Figure 4.1: Msk1 is a member of the MLL1 complex. Our results indicated that Msk1 can be a member of the 
MLL1 complex. We suggest that Msk1 deposits the H3S10p mark, which together with the H3K9ac mark 
stimulates H3K4me3 depositing by MLL1. Our data showed that in a cell cycle context this combination of 
marks may help exit of mitosis, supporting the hypothesis that MLL1 is a bookmarker during mitosis. This 
suggests that MLL1 activity can be directly regulated in response to MAPK signalling. 
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4.8 Perspectives 
So far it is not completely understood how MLL1 is regulated. However, given the 
connection of MLL1 with leukaemia, this is an essential question that needs to be addressed. 
In the progress of understanding MLL1 function we found that MLL1 binds to many genomic 
sites (~4000 sites, Chapter 3.2.2). This finding is consistent with previously reported ChIP-
ChIP data, which also showed that MLL1 occupanc y correlated with Pol II promoter 
occupancy(Guenther et al. 2005). We would like to investigate this interaction further using 
ChIP-Seq. As Pol II can be  paused (CTD domain is non-phosphorylated), or actively 
elongating (CTD domain is phosphorylated) (Phatnani & Greenleaf 2006), different 
antibodies could be used to distinguish whether MLL1 binding correlates with paused or 
elongating RNA Polymerase II. This study is underway. 
Our results also showed that the MLL1 distribution correlated with the Msk1 distribution on 
a third of sites and that MLL1 interacts physically with Msk1. These data suggest that they 
are found in one complex. The nature of this interaction remains elusive. It is known that in 
vitro a stable core complex of MLL1 and the WARD proteins (WDR, Ash2L, RbBP5 and Dpy-
30) is needed to support the enzymatic activity for H3K4 methylation (Ernst & Vakoc 2012). 
However, such a core complex is not the same as a stable functional complex in vivo, where 
not only the enzymatic function is needed, but also targeting and regulating elements. It has 
been established, that MLL1 forms a multi-protein complex on chromatin (Nakamura et al. 
2002, Steward et al. 2006, Patel et al. 2009), yet studies of MLL1 complex components have 
been controversial. For example, menin has been reported to be a stable member of this 
complex (Yokoyama et al. 2005), but a recent study on B-cell differentiation suggested that 
only a subgroup of genes are co-regulated by  MLL1 and menin, whilst a larger proportion of 
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genes are regulated through distinct pathways (Li et al. 2013). Those discrepancies give rise 
to questions about the composition of the MLL1 complex itself. It is possible that the MLL1 
complex consists of different proteins, depending on the cell type, or stage of 
differentiation, or even on the target site or stage of transcription. Current technologies only 
allow the investigation of cell populations, which are heterogeneous in respect to cell-cycle 
stage and state of transcription even in a single cell type, making it impossible to address this 
problem in the moment. However target site dependent MLL1 complex composition would 
explain why menin (Li et al. 2013), or here Msk1 seem to co-regulate only a small proportion 
of MLL1 target genes. Polycomb proteins, which also work as histone methyl-transferases, 
are known to form a small core complex with possible additional components (Aldiri & 
Vetter 2012). PRC2 (polycomb repressive complex 2) contains four core components: EZH 
1/2, SUZ12, EED and RBBP7/4. However on most PRC2 target sites PCL (Wang et al. 2004), 
AEBP2 (Kim et al. 2009) and JARID2 (Li et al. 2010) can be found. Although the precise 
function of these additional components is not yet completely understood (ie they are not 
essential for methyltransferase activity) it has been suggested that they modulate PRC2 
activity and promote DNA binding (Margueron & Reinberg 2011). A similar situation may be 
applicable for MLL1. 
It also remains elusive if Msk1 is a stable member of the MLL1 complex. CBP, an 
acetyltransferase within the MLL1 complex only interacts transiently to activate transcription 
(Ernst et al. 2001). Likewise, it is possible, that Msk1 only interacts with MLL1 after stress-
signals from the cell surface. A transient interaction with MLL1 to activate MLL1 target genes 
is consistent with the known Msk1 interaction of Msk1 and NFκB (Vermeulen et al. 2003) or 
CREB (Deak et al. 1998). Msk1 is activated upon cell-surface stimulation and phosphorylates 
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p65, which leads to the binding of NFκB p65 to its target sites and the interaction of CBP 
(Reber et al. 2009). Msk1 also phosphorylates and activates CREB dependent transcription. 
Whilst the significance of CBP to CREB activation by PKA is established, it is less clear if they 
are also involved in Msk1-dependent CREB activation (Naqvi et al. 2014). However, it 
emerges that CBP is a common co-activator for MLL1, NFκB and CREB, which leads to the 
speculation if CBP might mediate Msk1 dependent activation.  
Our data also showed that MLL1 and Msk1 interaction leads to cross-talk of histone 
modifications at MLL1 target genes. H3K9ac is deposited by acetyltransferases found in the 
MLL1 complex and H3S10p is added by Msk1. In vitro it was shown that these two marks 
together stimulate MLL1’s SET domain to deposit the H3K4me3 mark (Nightingale et al. 
2007). The down-regulation of MLL1 led to a decrease in the H3K4me3 mark and the 
H3K9ac/S10p mark. The same was observed for a down-regulation of Msk1, supporting our 
hypothesis that there is a close functional interaction between MLL1 and Msk1 and 
suggesting histone cross-talk is a means to activate MLL1. We haven’t investigated the 
possibility that Msk1 might phosphorylate MLL1 first to activate it and later after 
recruitment to chromatin, histone H3 to stimulate MLL1 activity further. It has been shown 
that MLL1 can be regulated by direct phosphorylation (Liu et al. 2010) and this course of 
events may explain why Msk1 only phosphorylates a small proportion of histone H3, 
although Msk1 itself doesn’t have any preferences in substrate choice in vitro (Arthur 2008).  
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